var title_f32_59_33712="Airway granulomas Endosc";
var content_f32_59_33712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Airway granulomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoscopic images of airway granulomas involving the vocal cords (left) and trachea (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33712=[""].join("\n");
var outline_f32_59_33712=null;
var title_f32_59_33713="Structure of a Mendelian randomization study";
var content_f32_59_33713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Structure of a Mendelian randomization study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a Mendelian randomization study, association 1 and 2 are estimated to determine the causal effect of the exposure (ie, the intermediate factor) on the outcome. Association 3 represents the usual association estimated in traditional observational studies which may be prone to the usual biases (ie, confounding, reverse-causality).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33713=[""].join("\n");
var outline_f32_59_33713=null;
var title_f32_59_33714="RA PIP soft tissue swelling x-ray";
var content_f32_59_33714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Soft tissue swelling and periarticular osteopenia of proximal interphalangeal joints in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain radiographs of the hand are magnified at the proximal interphalangeal joints of the third and fourth fingers showing soft tissue swelling (yellow arrows) and periarticular osteopenia (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33714=[""].join("\n");
var outline_f32_59_33714=null;
var title_f32_59_33715="Normal pap smear";
var content_f32_59_33715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal pap smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Douglas K. Hanks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33715=[""].join("\n");
var outline_f32_59_33715=null;
var title_f32_59_33716="Chloral hydrate: Patient drug information";
var content_f32_59_33716=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chloral hydrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/26/5542?source=see_link\">",
"     see \"Chloral hydrate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=see_link\">",
"     see \"Chloral hydrate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Somnote&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Chloral Hydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13154802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chloral hydrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Heart disease, kidney disease, liver disease, stomach irritation, or ulcer disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695410",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix the liquid with water, fruit juice, or ginger ale to make it taste better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699154",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not freeze liquid (syrup).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11235 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-18C17D12B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33716=[""].join("\n");
var outline_f32_59_33716=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149264\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149265\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13154802\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014633\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014632\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014637\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014638\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014640\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014635\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014636\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014641\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014642\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/26/5542?source=related_link\">",
"      Chloral hydrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/38/2662?source=related_link\">",
"      Chloral hydrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_59_33717="Phenylephrine (systemic): Patient drug information";
var content_f32_59_33717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenylephrine (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/47/6903?source=see_link\">",
"     see \"Phenylephrine (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/23/13686?source=see_link\">",
"     see \"Phenylephrine (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Medi-First&reg; Sinus Decongestant [OTC];",
"     </li>",
"     <li>",
"      Medi-Phenyl [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's Decongestant [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&reg; Congestion [OTC];",
"     </li>",
"     <li>",
"      Sudafed PE&trade; Nasal Decongestant [OTC];",
"     </li>",
"     <li>",
"      Sudogest&trade; PE [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with some other drug to numb an area.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702730",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenylephrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703538",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A fast heartbeat or high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12287 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33717=[""].join("\n");
var outline_f32_59_33717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504766\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025788\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025790\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025789\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025794\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025795\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025797\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025792\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025793\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025798\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025799\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_59_33718="CT panc adenocarcinoma";
var content_f32_59_33718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Typical appearance of pancreatic adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multidetector enhanced CT of two different patients, in which ill-defined hypodense, solid tumors are present in the head and uncinate process of the pancreas (arrows). Typically, normal pancreatic tissue enhances to a greater extent than do pancreatic adenocarcinomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Rocio Perez-Johnston.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33718=[""].join("\n");
var outline_f32_59_33718=null;
var title_f32_59_33719="Examination of the jugular venous pulse";
var content_f32_59_33719=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Examination of the jugular venous pulse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33719/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33719/contributors\">",
"     Kanu Chatterjee, MB, FRCP, FCCP, FACC, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33719/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33719/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33719/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33719/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/59/33719/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of the jugular venous pressure and pulse provides information regarding hemodynamic changes in the right side of the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4526140\">",
"    <span class=\"h1\">",
"     INTERNAL VERSUS EXTERNAL JUGULAR VEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is preferable to examine the internal rather than external jugular veins since the internal jugular veins are in a direct line with the superior vena cava and right atrium whereas the external jugular veins are not in a direct line with the superior vena cava and connect with it after negotiating two almost 90 degree angles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/1\">",
"     1",
"    </a>",
"    ]. There are valves between the superior vena cava and both internal and external jugular veins; however elevated venous pressure can be transmitted through the venous valves. The external jugular venous bulb is a site for thrombus formation, which can cause partial obstruction of the external jugular veins.",
"   </p>",
"   <p>",
"    Partial compression of the left innominate vein is usually relieved during modest inspiration as the diaphragm and the aorta descend and the pressure in the two internal jugular veins becomes equal. However partial obstruction of the left innominate vein from compression by the aorta may persist, particularly in relatively elderly patients, impairing transmission of right atrial pressure to the left internal jugular vein; this is also the most common cause of unequal pressures between right and left internal jugular veins. There is better transmission of right atrial pressures and pulses to the right internal jugular vein since the right innominate and internal jugular veins are in a direct line with the superior vena cava. Thus, examination of the right internal jugular venous pulse is preferable for assessing the hemodynamic changes in the right side of the heart. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36807?source=see_link\">",
"     \"Cardiac catheterization techniques: Normal hemodynamics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     JUGULAR PULSATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal jugular venous pulse wave or right atrial pressure wave recordings usually consist of three positive waves, a, c and v, and two negative waves, x and y [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/2\">",
"     2",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef58343 \" href=\"mobipreview.htm?35/53/36701\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36807?source=see_link\">",
"     \"Cardiac catheterization techniques: Normal hemodynamics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The positive a wave is caused by the right atrial pressure transmitted to the jugular veins during right atrial systole. The a wave peaks just before or during the first heart sound (S1) and before the onset of ventricular ejection (carotid pulse upstroke).",
"     </li>",
"     <li>",
"      Atrial relaxation initiates the descent of the a wave and this is usually interrupted by the c wave. In the right atrial pressure tracing, the c wave is recognized with the onset of right ventricular systole and presumably occurs from bulging of the tricuspid valve into the right atrium as well as from transmission of the adjacent carotid artery pulsation. The c wave of the jugular venous pulse generally cannot be distinguished by clinical examination although it is usually apparent in the right atrial pressure tracing.",
"     </li>",
"     <li>",
"      Following the a and c waves, the x descent is a negative wave that occurs in late systole due to the delay in transmission of the pulse. Right atrial relaxation appears to be the primary mechanism for the x descent, although downward displacement of the tricuspid valve and right atrioventricular annulus during right ventricular ejection also contributes to the fall in right atrial pressure.",
"     </li>",
"     <li>",
"      Terminating the x descent is the v wave. The mechanism of the v wave is the rise in right atrial and jugular venous pressure due to continued inflow of blood to the venous system during late ventricular systole when the tricuspid valve is still closed. The peak of the normal v wave is immediately after ventricular systole; the normal v wave coincides with the downslope of the carotid pulse after the peak amplitude is felt.",
"     </li>",
"     <li>",
"      The descending limb of the v wave, termed the y descent, is caused by the opening of the tricuspid valve and the rapid inflow of blood to the right ventricle from the right atrium and the venous system. The initial y descent occurs during the rapid filling phase of the right ventricle, and the right ventricular third heart sound (S3) corresponds to the nadir of the y wave. The ascending limb of the y wave occurs during continued inflow of blood to the venous system and right ventricle after the rapid filling phase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is often difficult to distinguish a and v waves or x and y descents during tachycardia. Not infrequently, only one positive and one negative wave are recognized. Carotid massage may be necessary to slow the heart rate and allow better analysis of the jugular venous pulse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=see_link&amp;anchor=H4#H4\">",
"     \"Vagal maneuvers\", section on 'Carotid sinus massage'",
"    </a>",
"    .) In patients with atrial fibrillation, the jugular venous pulse is irregular and usually only v and y waves are appreciated. In atrial flutter, occasionally flutter waves are recognized, and the frequency of the flutter waves are higher than the arterial pulse rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Distinguishing venous and arterial pulsations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating the venous and arterial pulse can be difficult. Some distinguishing features are helpful (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33013?source=see_link\">",
"     \"Examination of the arterial pulse\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During inspection, the venous pulse is recognized by its double undulation (a and v waves), frequently associated with relatively sharper inward movement. The dominant movement in the venous pulse is always inward (the x descent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/3\">",
"       3",
"      </a>",
"      ]. The double undulation character of the venous pulse is lost during atrial fibrillation due to the absence of an a wave associated with atrial systole. The venous pulse still can be recognized from its dominant inward movement.",
"     </li>",
"     <li>",
"      The carotid pulse is more easily visible medially and higher in the neck, generally in the submandibular region. It is characterized by a single, sharp outward movement.",
"     </li>",
"     <li>",
"      The amplitude of the venous pulse can be manipulated by changing the venous pressure. It can be decreased by raising the level of the head and trunk above the level of the right atrium (eg, sitting or standing) which reduces venous return and pressure, or increased by enhancing the venous return to the right side of the heart by raising the legs or compressing the abdomen (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Hepatojugular reflux'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Pressure in the neck veins generally decreases appreciably during inspiration, giving the impression of \"inspiratory collapse\". In contrast, the arterial pulse amplitude does not change significantly during inspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In certain conditions the \"inspiratory collapse\" of the jugular venous pulse does not occur. Venous pressure may actually increase with constrictive pericarditis, massive pulmonary embolism, and right ventricular infarction (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Kussmaul's sign'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gentle to moderate compression at the root of the neck obliterates the venous pulse in the neck above the level of compression, while the arterial pulsation remains visible. This maneuver is particularly useful for separating a very prominent venous pulsation from the carotid artery pulsation. Compression at the root of the neck may cause distention of the veins distal to the obstruction by impeding flow of blood to the heart, although pulsation will be absent due to blockade of the retrograde transmission of the pulse wave from the right atrium.",
"     </li>",
"     <li>",
"      The arterial pulse is more easily palpable than the venous pulse. Occasionally the venous pulse also becomes palpable when venous pressure is extremely high and the veins are distended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abnormalities of the a wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevation in a waves indicates obstruction to right atrial emptying. Several arrhythmias also are associated with changes in the a wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Increased a waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormally large a waves occurring with each sinus beat indicate increased resistance to right atrial emptying during atrial systole. Increased resistance may occur at or beyond the tricuspid valve.",
"   </p>",
"   <p>",
"    A systematic approach is useful in determining the potential etiology of the large a wave. A large a wave in the jugular venous pulse is more likely to occur in the absence of interatrial or interventricular septal defects when atrial contraction can generate higher pressure. Thus, prominent a waves are uncommon in trilogy and tetralogy of Fallot or in Eisenmenger syndrome.",
"   </p>",
"   <p>",
"    Causes of an increased a wave due to tricuspid valvular abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rheumatic tricuspid stenosis",
"     </li>",
"     <li>",
"      Right atrial myxoma",
"     </li>",
"     <li>",
"      Carcinoid heart disease",
"     </li>",
"     <li>",
"      Lupus endocarditis",
"     </li>",
"     <li>",
"      Right atrial thrombus",
"     </li>",
"     <li>",
"      Congenital tricuspid stenosis",
"     </li>",
"     <li>",
"      Tricuspid atresia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Important physical findings associated with a tall a wave due to tricuspid valvular stenotic abnormalities (except tricuspid atresia) include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A mid-diastolic rumble heard along the left lower sternal border that increases in intensity during inspiration",
"     </li>",
"     <li>",
"      Tricuspid opening snap",
"     </li>",
"     <li>",
"      Slow y descent in the jugular venous pulse",
"     </li>",
"     <li>",
"      Presystolic hepatic pulsation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes of an increased a wave due to increased resistance distal to the tricuspid valve include right ventricular outflow obstruction due to pulmonary valve stenosis or right ventricle hypertrophy. Important physical findings associated with pulmonary valve stenosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long ejection systolic murmur that increases in intensity along the left sternal border",
"     </li>",
"     <li>",
"      Widely split S2 with decreased intensity of the pulmonary component",
"     </li>",
"     <li>",
"      Sustained left parasternal impulse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased a wave may also be due to right ventricular hypertrophy without outflow obstruction resulting from precapillary pulmonary arterial hypertension, peripheral pulmonary artery branch stenosis, or postcapillary pulmonary artery hypertension. Important physical findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sustained left parasternal impulse",
"     </li>",
"     <li>",
"      Narrowly split S2 with P2 louder than A2 and P2 transmitted to the mitral area",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Bernheim a wave is the prominent a wave observed in some patients with left ventricular hypertrophy. It is probably due to atrial interaction which has been attributed to shared interatrial myocardial fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of arrhythmias can be suspected at the bedside by analysis of the character of the venous pulse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The a wave is absent in atrial fibrillation. The a wave may also be absent when the right atrium is dilated and does not possess effective mechanical systole, as in severe Ebstein's anomaly and a giant silent right atrium. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=see_link\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flutter waves are occasionally recognized in atrial flutter.",
"     </li>",
"     <li>",
"      Increased and prominent a waves that are regular often occur during an atrioventricular nodal reentrant or atrioventricular reentrant tachycardia due to simultaneous or almost simultaneous atrial and ventricular activation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"       \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A cannon wave is a large positive venous pulse wave produced by atrial contraction during ventricular systole when the tricuspid valve is closed. Cannon a waves can be seen with several rhythm abnormalities. The most common cause of irregularly occurring cannon waves is atrial, ventricular, or junctional premature beats. In these circumstances, the pulse is also irregular. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=see_link\">",
"       \"Supraventricular premature beats\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=see_link\">",
"       \"Prevalence and evaluation of ventricular premature beats\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Irregular cannon waves associated with a regular, slow pulse, suggest complete atrioventricular block; the irregular waves are caused by atrial systole occurs randomly during ventricular diastole and systole. Complete atrioventricular block is also associated with varying intensity of the first heart sound. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=see_link\">",
"     \"Third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular cannon waves occur during a junctional rhythm, slow ventricular tachycardia, 2:1 atrioventricular block, and bigeminy. Regular cannon waves may also occur in first-degree atrioventricular block with a markedly prolonged PR interval and atrial systole occurring during the preceding ventricular systole.",
"   </p>",
"   <p>",
"    Analysis of the venous pulse and the intensity of S1 are occasionally helpful in the differential diagnosis of wide complex tachycardia. Irregularly occurring cannon waves and varying intensity of S1 suggest atrioventricular dissociation and, hence, ventricular tachycardia. Absence of cannon waves and constant intensity of S1 suggest supraventricular tachycardia with aberrant conduction. It needs to be emphasized, however, that the diagnosis of dysrhythmia can only be suspected from the abnormalities of the venous pulse; its diagnosis must be confirmed by the electrocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Abnormalities of the v wave",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tall v waves are most commonly the result of tricuspid valve regurgitation (Lancisi sign). The diagnosis of tricuspid regurgitation frequently can be made by observing the amplitude of the v wave and the character of the y descent. In patients with mild tricuspid regurgitation, there may not be any alternation in the jugular venous pulse. Severe tricuspid regurgitation produces an early large v wave (regurgitant wave) which occurs with the onset of right ventricular systole; the amplitude of the v wave depends upon the regurgitant volume and right atrial compliance. The v wave is followed by a steep y descent, the result of the increased pressure gradient across the tricuspid valve, which allows rapid inflow to the right ventricle and decompression of the right atrium in early diastole.",
"   </p>",
"   <p>",
"    The regurgitant wave of significant tricuspid regurgitation occurs concurrently with the carotid pulse and can be easily recognized by timing the onset with the carotid pulse upstroke. Associated with tricuspid regurgitation is a pansystolic murmur along the lower right and left sternal border that increases in intensity during inspiration, and systolic pulsation of the liver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, severe tricuspid regurgitation may be present without any obvious v wave in the jugular venous pulse. This is particularly true in patients with a markedly dilated right atrium.",
"   </p>",
"   <p>",
"    In some patients with an arteriovenous fistula for hemodialysis, a prominent v wave is seen due to shunting of blood into the venous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Atrial septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prominent v wave is occasionally detected in patients with atrial septal defect without significant pulmonary arterial hypertension and in the absence of tricuspid regurgitation. The mechanism remains unclear. Concomitant systemic venous return and left-to-right shunting during ventricular systole may cause a rapid increase in right atrial pressure and, hence, a prominent v wave. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Abnormalities of the x descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prominent x descent occurs when there is vigorous right ventricular contraction which occurs in some patients with atrial septal defect and in early stage cardiac tamponade. In severe cardiac tamponade the x descent is attenuated. The x descent is also attenuated in patients with severe tricuspid regurgitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abnormalities of the y descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the y descent can be seen with obstruction to right atrial outflow in which the y descent is slow, or with constrictive pericarditis in which the y descent is steep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Slow y descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A slow y descent may suggest tricuspid valve obstruction, which can be confirmed by auscultatory findings of tricuspid stenosis. However, a slow y descent may also occur in the presence of severe right ventricular hypertrophy, as in pulmonary valve or infundibular stenosis when resistance to early right ventricular filling is increased.",
"   </p>",
"   <p>",
"    The presence of a steep y descent is strong evidence against significant tricuspid valve obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sharp y descent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sharp y descent without a prominent v wave occurs in constrictive pericarditis, restrictive cardiomyopathy, or in severe right-sided heart failure with a markedly elevated systemic venous pressure. A rapid y descent following a large v (regurgitant) wave is characteristic of tricuspid regurgitation.",
"   </p>",
"   <p>",
"    In constrictive pericarditis and restrictive cardiomyopathy, the mean jugular venous pressure is elevated and the amplitudes of the a and v waves are usually similar. The striking movement in the jugular venous pulse is the sharp inward y descent.",
"   </p>",
"   <p>",
"    It is difficult to differentiate between constrictive pericarditis and restrictive cardiomyopathy at the bedside. A left parasternal diastolic impulse and pericardial \"knock\" favors constrictive pericarditis; physical findings indicating significant right ventricular systolic and pulmonary arterial hypertension are more common in restrictive cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients with constrictive pericarditis, a steeper x descent may be present instead of a sharp y descent. The mechanism of a sharp x descent is not clear; it is more likely to occur in effusive, constrictive pericarditis.",
"   </p>",
"   <p>",
"    In cardiac tamponade, the mean jugular venous pressure is elevated and x and y descents are not prominent. An elevated mean jugular venous pressure with a quiet precordium and the absence of any physical findings of pulmonary arterial hypertension should initiate a search for pericardial effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HEPATOJUGULAR REFLUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raising the legs or abdominal compression increases venous return and pressure and facilitates analysis of the jugular venous pulse. The hepatojugular or abdominojugular reflux is assessed by applying firm, sustained pressure for 10 to 15 seconds over the upper abdomen while the patient is breathing quietly. In normal subjects this maneuver transiently increases jugular pressure by only approximately 1-3 cm. In patients with right ventricular failure, however, sustained elevation of venous pressure usually greater than 3 cm is observed during continued compression (positive hepatojugular reflux).",
"   </p>",
"   <p>",
"    The mechanism for this phenomenon has not been clearly elucidated. It is assumed that a failing right ventricle is unable to respond normally to the increased preload caused by increased venous return with abdominal compression and elevated intraabdominal pressure. In addition, a raised diaphragm during abdominal compression compromises cardiac filling by decreasing the intrathoracic and mediastinal volumes available for cardiac expansion. Thus, abnormal elevation of systemic venous pressure may be the consequence of volume expansion and a raised diaphragm during abdominal compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, in the absence of isolated right heart failure, a positive hepatojugular reflux is usually associated with pulmonary capillary wedge pressure of 15 mm Hg or higher such as in patients with dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/7\">",
"     7",
"    </a>",
"    ]. The mechanism is not entirely clear; however it may be due to impaired right ventricular compliance during abdominal compression in patients with left heart failure due to dilated cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     JUGULAR VENOUS (RIGHT ATRIAL) PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimation of venous pressure is one of the methods used to assess volume status. The normal venous pressure is 1 to 8 cm of water (or blood) or 1 to 6 mmHg (1.36 cm of water is equal to 1.0 mmHg). Thus, a low value is consistent with but not diagnostic of volume depletion since it may be normal. Another important use is to distinguish the different causes of generalized edema: the venous pressure is elevated in heart failure and renal failure but is usually normal in cirrhosis (unless there is tense ascites) or nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of edema in adults\", section on 'Distribution of edema and central venous pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The venous pressure can be estimated from either the height of internal jugular venous pulsations or from the height of the column of blood in the external jugular vein. With both techniques, right atrial pressure is classically approximated by adding 5 cm to the height of the venous column, since it is assumed that the right atrium is located about 5 cm below the sternal angle. However, this assumption may lead to",
"    <strong>",
"     underestimation",
"    </strong>",
"    of right atrial pressure.",
"   </p>",
"   <p>",
"    A careful clinical study used CT scan measurements in 160 patients to determine the distance between the sternal angle and the level of the right atrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/8\">",
"     8",
"    </a>",
"    ]. The median value for the vertical distance was 5.4 cm in the supine position. However, when the CT images of the torso were rotated to 30&ordm;, 45&ordm; and 60&ordm;, the median vertical distance was 8, 9.7, and 9.8 cm, respectively. Furthermore, there was wide range of values among patients (eg, 5 to 13 cm at 30&ordm;). It is recommended that 10 cm should be added rather than 5 cm if the torso is elevated greater than 45 degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations illustrate the difficulties in accurately determining the right atrial pressure by physical examination. However, this error is not so limiting since, in the majority of patients, the main value comes from determining whether the right atrial pressure is low or high, and how it changes over time or in response to medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Internal jugular venous pulsations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, examination of internal jugular venous pulsations has generally been preferred for estimating central venous pressure as well as right-sided hemodynamics. However, this technique may be difficult to interpret when assessing venous pressure, particularly for the inexperienced examiner. In many patients, examination of the external jugular veins can provide an accurate estimate of venous pressure. (See",
"    <a class=\"local\" href=\"#H4526140\">",
"     'Internal versus external jugular vein'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Examination of the neck veins should be performed in adequate light, keeping the head of the patient in the midline position at 30&ordm; to 45&ordm; or slightly turned to the opposing side. Once the venous pulse is recognized, the venous pressure is estimated by noting the height of the oscillating top of the venous pulse above the sternal angle.",
"   </p>",
"   <p>",
"    The venous pressure may be either too high or too low when the venous pulse is not easily recognized; the position of the neck and trunk should be elevated or lowered accordingly. However, the neck and trunk position to obtain maximum venous pulsation vary from patient to patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the venous pressure is high, the venous pulsations are best seen when the trunk is elevated to 90&ordm;.",
"     </li>",
"     <li>",
"      In the presence of normal or low venous pressure, examination is performed with the patient in the supine or horizontal position. In the horizontal position, the venous pulsation is usually visible in the neck when the right atrial pressure is normal. If the neck veins collapse in the horizontal position, subnormal right atrial pressure is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     External jugular vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the limitations discussed above, in many patients, the venous pressure can be estimated with sufficient accuracy by examination of the external jugular vein, which runs across the sternocleidomastoid muscle. (See",
"    <a class=\"local\" href=\"#H4526140\">",
"     'Internal versus external jugular vein'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The patient should initially be recumbent, with the trunk elevated at 15 to 30&ordm; and the head turned slightly away from the side to be examined. The external jugular vein can be identified by placing the forefinger just above the clavicle and pressing lightly. This will occlude the vein, which will then distend as blood continues to enter from the cerebral circulation. The external jugular vein usually can be seen more easily by shining a beam of light obliquely across the neck.",
"   </p>",
"   <p>",
"    At this point, the vein should be occluded superiorly (to prevent distention by continued blood flow) and the occlusion at the clavicle released. The venous pressure can now be measured, since it will be approximately equal to the vertical distance between the upper level of the fluid column within the vein and the level of the right atrium (generally estimated as being 5 to 6 cm posterior to the sternal angle of Louis). If the vein is distended throughout its length, the patient's trunk should be elevated to 45&ordm; or even 90&ordm; until an upper level can be seen. In a patient with a markedly increased venous pressure due to right ventricular failure, the external jugular vein may remain distended even when the patient is upright.",
"   </p>",
"   <p>",
"    There are some limitations to the use of this technique:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The external jugular vein may not become visible when it is occluded at the clavicle, particularly in those patients with a fat neck. If this occurs, it should not be assumed that the venous pressure is very low. Rather, the venous pressure should be measured in some other way, such as estimation of the level of pulsations in the internal jugular vein or directly by insertion of a catheter into the right atrium.",
"     </li>",
"     <li>",
"      A much less common problem is kinking or obstruction (eg, by valves or compression) of the external jugular vein at the base of the neck . In this setting, there is an increase in the external jugular venous pressure that does not reflect a similar change in right atrial pressure. This possibility should be suspected if the other jugular vein is visible and not distended or if an elevated venous pressure is found in a patient with no evidence or history of cardiac, pulmonary, or renal disease. Examination of internal jugular venous pulsations is warranted in such patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach that has been proposed in patients with a difficult jugular vein examination (such as obese patients or those with short necks) is the use of ultrasonography for the estimation of central venous pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/9\">",
"     9",
"    </a>",
"    ]. A more common technique is echocardiographic estimation of right atrial pressure according to the size of the inferior vena cava and the degree of its inspiratory collapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31528?source=see_link&amp;anchor=H21#H21\">",
"     \"Echocardiographic evaluation of the atria and appendages\", section on 'Vena cava'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical significance of elevated values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated jugular venous pressure indicates increased right atrial pressure which can be caused by various pathologic conditions such as right ventricular failure (eg, cardiomyopathy), restriction of right atrial and right ventricular filling (eg, cor pulmonale, pulmonary hypertension, constrictive pericarditis), fluid overload due to renal disease (eg, poststreptococcal glomerulonephritis), tricuspid valve incompetence, functional and organic obstruction of the tricuspid valve, and superior vena cava obstruction.",
"   </p>",
"   <p>",
"    The presence of an elevated jugular venous pressure also has prognostic significance, being associated with a higher risk of progression to symptomatic heart failure in those with asymptomatic left ventricular dysfunction and a higher risk of hospitalization for heart failure or death from left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The character of the venous pulse and associated physical findings may help distinguish venous obstruction from other causes of elevated venous pressure. When elevated venous pressure is caused by elevated right atrial pressure, venous pulsations persist. In contrast, bilateral elevation of the mean jugular venous pressure in the absence of venous pulsation should raise suspicion of superior vena cava obstruction. Findings associated with superior vena caval obstruction include prominent distended veins in the upper extremities and in the upper torso with lateral thoracic veins draining caudally to the veins below the umbilicus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Kussmaul's sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean level of venous pressure normally declines during inspiration but the amplitude of the a wave increases. Lack of a decrease or an increase in jugular venous pressure during inspiration, called Kussmaul's sign, is abnormal and is observed in a number of conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Constrictive or effusive pericarditis; other findings suggestive of chronic pericardial constriction include sharp y descent, diastolic left parasternal impulse, and pericardial knock. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=see_link\">",
"       \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Restrictive cardiomyopathy",
"     </li>",
"     <li>",
"      Predominant right ventricular infarction; in patients with inferior or inferoposterior acute myocardial infarction, the presence of Kussmaul's sign almost invariably indicates predominant right ventricular infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33719/abstract/5,11,12\">",
"       5,11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Massive pulmonary embolism",
"     </li>",
"     <li>",
"      Partial obstruction of the vena cavae",
"     </li>",
"     <li>",
"      Right atrial and right ventricular tumors",
"     </li>",
"     <li>",
"      Occasionally tricuspid stenosis and congestive heart failure",
"     </li>",
"     <li>",
"      Rarely cardiac tamponade",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism of Kussmaul's sign in these conditions is not entirely clear. Increased resistance to right atrial filling during inspiration appears to be a contributory factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5889533\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the jugular venous pressure (particularly in the right internal jugular vein) allows estimation of right atrial pressure, and, in absence of tricuspid regurgitation, right ventricular pressure. Thus it is possible to diagnose right ventricular failure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical significance of elevated values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Analysis of the&nbsp;character of the jugular venous pulse enables bedside diagnosis of many cardiac conditions such as constrictive pericarditis and tricuspid regurgitation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sharp y descent'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Kussmaul's sign'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Abnormalities of the v wave'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A positive hepatojugular reflux&nbsp;is a helpful clinical sign of systolic heart failure in adults. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hepatojugular reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal findings on jugular venous examination should always be interpreted in conjunction with other findings to establish the diagnosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Clinical significance of elevated values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in jugular venous pressure can be used to estimate changes in a patient&rsquo;s volume status. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Jugular venous (right atrial) pressure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/1\">",
"      Constant J. Using internal jugular pulsations as a manometer for right atrial pressure measurements. Cardiology 2000; 93:26.",
"     </a>",
"    </li>",
"    <li>",
"     Chatterjee, K. Physical Examination. In: Textbook of Cardiovascular Medicine, Topol, EJ (Eds), Lippincott-Raven Publishers, Philadelphia 1998. p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/3\">",
"      Devine PJ, Sullenberger LE, Bellin DA, Atwood JE. Jugular venous pulse: window into the right heart. South Med J 2007; 100:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/4\">",
"      Henein MY, Xiao HB, Brecker SJ, Gibson DG. Berheim \"a\" wave: obstructed right ventricular inflow or atrial cross talk? Br Heart J 1993; 69:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/5\">",
"      Dell'Italia LJ, Starling MR, O'Rourke RA. Physical examination for exclusion of hemodynamically important right ventricular infarction. Ann Intern Med 1983; 99:608.",
"     </a>",
"    </li>",
"    <li>",
"     Cohn, J, Hamosh, P. Experimental observations on pulsus paradoxus and hepatojugular reflux. In: Pericardial Disease, Reddy, PS (Eds), Raven Press, New York 1982. p.249.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/7\">",
"      Ewy GA. The abdominojugular test: technique and hemodynamic correlates. Ann Intern Med 1988; 109:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/8\">",
"      Seth R, Magner P, Matzinger F, van Walraven C. How far is the sternal angle from the mid-right atrium? J Gen Intern Med 2002; 17:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/9\">",
"      Jang T, Aubin C, Naunheim R, Char D. Ultrasonography of the internal jugular vein in patients with dyspnea without jugular venous distention on physical examination. Ann Emerg Med 2004; 44:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/10\">",
"      Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/11\">",
"      Baigrie RS, Haq A, Morgan CD, et al. The spectrum of right ventricular involvement in inferior wall myocardial infarction: a clinical, hemodynamic and noninvasive study. J Am Coll Cardiol 1983; 1:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33719/abstract/12\">",
"      Bellamy GR, Rasmussen HH, Nasser FN, et al. Value of two-dimensional echocardiography, electrocardiography, and clinical signs in detecting right ventricular infarction. Am Heart J 1986; 112:304.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1076 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-F2EAE850DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33719=[""].join("\n");
var outline_f32_59_33719=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5889533\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4526140\">",
"      INTERNAL VERSUS EXTERNAL JUGULAR VEIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      JUGULAR PULSATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Distinguishing venous and arterial pulsations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abnormalities of the a wave",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Increased a waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Abnormalities of the v wave",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Abnormalities of the x descent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abnormalities of the y descent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Slow y descent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sharp y descent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HEPATOJUGULAR REFLUX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      JUGULAR VENOUS (RIGHT ATRIAL) PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Internal jugular venous pulsations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      External jugular vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical significance of elevated values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Kussmaul's sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5889533\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1076\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1076|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/53/36701\" title=\"figure 1\">",
"      Right atrial pressure tracing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36807?source=related_link\">",
"      Cardiac catheterization techniques: Normal hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=related_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31528?source=related_link\">",
"      Echocardiographic evaluation of the atria and appendages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33013?source=related_link\">",
"      Examination of the arterial pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9320?source=related_link\">",
"      Prevalence and evaluation of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=related_link\">",
"      Supraventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15285?source=related_link\">",
"      Third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_59_33720="Head lice nits";
var content_f32_59_33720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74790%7EPC%2F56619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74790%7EPC%2F56619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Head lice nits",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous head lice nits are attached to the hairs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Head louse nit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic view of a head louse nit attached to a strand of hair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33720=[""].join("\n");
var outline_f32_59_33720=null;
var title_f32_59_33721="Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)";
var content_f32_59_33721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33721/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33721/contributors\">",
"     Anthony Bleyer, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33721/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33721/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33721/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/59/33721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant interstitial kidney disease (ADIKD) is a rare and heterogeneous genetic disorder. There are approximately 200 families in the United States suffering from this condition. Individual families may have a large number of affected individuals due both to autosomal dominant inheritance and to the late onset of chronic kidney disease. Underreporting due to incorrect diagnosis may contribute to the low estimated prevalence.",
"   </p>",
"   <p>",
"    ADIKD is characterized by the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant inheritance",
"     </li>",
"     <li>",
"      Slowly progressive kidney disease, with impaired renal function typically appearing in the teenage years, and end-stage renal disease usually occurring between the ages of 20 and 70",
"     </li>",
"     <li>",
"      A bland urine sediment with no or minimal proteinuria",
"     </li>",
"     <li>",
"      Medullary cysts may be seen on renal ultrasonography but are",
"      <strong>",
"       not",
"      </strong>",
"      present in most cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111033540\">",
"    <span class=\"h1\">",
"     TERMINOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology for this condition is confusing, leading to difficulties in diagnosis and classification. Other names that have been commonly used for ADIKD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medullary cystic kidney disease (MCKD) &minus; MCKD is another term that has been used for ADIKD. However, MCKD is a misnomer because medullary cysts occur sporadically in patients with ADIKD, and it is unclear if they are even part of the syndrome.",
"     </li>",
"     <li>",
"      Familial juvenile hyperuricemic nephropathy (FJHN) &ndash; This term was first used by pediatric nephrologists, and is essentially synonymous with what adult nephrologists call MCKD.",
"     </li>",
"     <li>",
"      Uromodulin-associated kidney disease (UAKD) &ndash; This term refers to the large subgroup of families with ADIKD that have mutations in the gene encoding uromodulin (Tamm-Horsfall protein).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ADIKD is included in the",
"    <span class=\"nowrap\">",
"     nephronophthisis/medullary",
"    </span>",
"    cystic kidney disease complex. Nephronophthisis refers to autosomal recessive (not dominant) conditions that typically present in childhood and lead to end-stage renal disease by the teenage years or early 20s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, ADIKD is an autosomal dominant condition that tends to present later in life, although it can occasionally present in children under age 10 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/56/10120?source=see_link\">",
"     \"Genetics and pathogenesis of nephronophthisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111033564\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of ADIKD is based upon the underlying genetic mutation. There are at least four types of ADIKD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in the UMOD gene, which encodes uromodulin (Tamm-Horsfall protein), are present in the majority of cases of ADIKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/3-17\">",
"       3-17",
"      </a>",
"      ]. This condition has variably been called uromodulin-associated kidney disease (UAKD), medullary cystic kidney disease type 2 (MCKD2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/5,6\">",
"       5,6",
"      </a>",
"      ], and familial juvenile hyperuricemic nephropathy (FJHN).",
"     </li>",
"     <li>",
"      Mutations in the REN gene, which encodes renin, have been identified as causes of ADIKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations in the MUC1 gene, which encodes mucin 1, have been described in some families [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/20-24\">",
"       20-24",
"      </a>",
"      ]. This form of ADIKD has often been referred to as medullary cystic kidney disease type 1 (MCKD1).",
"     </li>",
"     <li>",
"      Mutations in other, as yet unidentified genes, may account for some cases. Some families with ADIKD have been identified that do not have mutations in either UMOD, REN, or MUC1 genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/25\">",
"       25",
"      </a>",
"      ]. Although genetically different, these patients present with slowly progressive interstitial kidney disease and an autosomal dominant form of inheritance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341952946\">",
"    <span class=\"h1\">",
"     GENETICS AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Uromodulin-associated kidney disease (UAKD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;UAKD has also been referred to as medullary cystic kidney disease type 2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], familial juvenile hyperuricemic nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/4,8\">",
"     4,8",
"    </a>",
"    ], hereditary nephropathy associated with hyperuricemia and gout [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/10\">",
"     10",
"    </a>",
"    ], uromodulin storage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7\">",
"     7",
"    </a>",
"    ], and glomerulocystic kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. All of these terms have been used to describe families with mutations in the UMOD gene. A clinical distinction among these terms is",
"    <strong>",
"     not",
"    </strong>",
"    warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     UAKD genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;UAKD is due to mutations in the UMOD gene on chromosome 16p12, which encodes uromodulin (Tamm-Horsfall mucoprotein) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/2-5,7,9,11-15\">",
"     2-5,7,9,11-15",
"    </a>",
"    ]. Almost all patients have mutations in exons 4 or 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/2,5,7,9,12,26\">",
"     2,5,7,9,12,26",
"    </a>",
"    ], although rare families have mutations in exons 6 or 8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/15,26\">",
"     15,26",
"    </a>",
"    ]. In addition, certain polymorphisms in the UMOD gene have been associated with an increased risk of chronic kidney disease in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than one-half of the defects identified in the uromodulin gene are missense mutations resulting in the deletion or addition of a cysteine residue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7\">",
"     7",
"    </a>",
"    ]. The mutant uromodulin proteins are unable to assemble properly and cannot exit the endoplasmic reticulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], resulting in uromodulin accumulation within the cells of the thick ascending limb of the loop of Henle.",
"   </p>",
"   <p>",
"    Although UAKD is an autosomal dominant disease, homozygosity for uromodulin disorders has been reported in a consanguineous family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/17\">",
"     17",
"    </a>",
"    ]. These patients had an earlier age of onset of hyperuricemia and progressed more rapidly to end-stage renal disease than heterozygotes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     UAKD pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uromodulin is produced exclusively in the thick ascending limb of the loop of Henle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/30\">",
"     30",
"    </a>",
"    ]. It is an insoluble protein whose sticky, adherent properties are probably important in maintaining the water-tight integrity of the thick ascending limb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Uromodulin also appears to facilitate intracellular transport of both the Na-K-2Cl furosemide-sensitive transporter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/32\">",
"     32",
"    </a>",
"    ] and the ROMK potassium channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/33\">",
"     33",
"    </a>",
"    ] on the apical surface of the thick ascending loop tubular cells (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"mobipreview.htm?30/62/31725\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In patients with UAKD, intracellular accumulation of abnormal uromodulin proteins can lead to tubular cell atrophy and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/5,27,29\">",
"     5,27,29",
"    </a>",
"    ]. In addition, the abnormal uromodulin appears to impair the synthesis and secretion of normal uromodulin produced from the unaffected allele, resulting in a marked reduction in urinary uromodulin excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/5,34\">",
"     5,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two major pathophysiologic effects of uromodulin gene mutations are hyperuricemia and progressive chronic kidney disease (CKD):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperuricemia results from reduced urate excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/10,11,35,36\">",
"       10,11,35,36",
"      </a>",
"      ]. How this occurs is not clearly understood. One hypothesis is that accumulation of abnormal uromodulin in thick ascending limb cells leads sequentially to impaired sodium chloride reabsorption, mild renal salt wasting, volume contraction, and a secondary increase in proximal urate reabsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/5,35,36\">",
"       5,35,36",
"      </a>",
"      ], which restores volume status to normal but leads to hypouricosuric hyperuricemia.",
"     </li>",
"     <li>",
"      Progressive CKD may be related to tubular cell death in the thick ascending limb due to accumulation of mutant uromodulin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/5,28\">",
"       5,28",
"      </a>",
"      ]. There is no proven role for uric acid accumulation. Kidney biopsy reveals tubulointerstitial disease but no uric acid crystals. The possible therapeutic role for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      in slowing renal disease progression is discussed below. (See",
"      <a class=\"local\" href=\"#H341954671\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to its effects on water impermeability and ion transport in the thick ascending limb, rodent data suggest that uromodulin protects against urinary tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/31,37\">",
"     31,37",
"    </a>",
"    ] and inhibits formation of renal calculi. However, patients with UAKD do not have an increased incidence of urinary tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/2\">",
"     2",
"    </a>",
"    ] or kidney stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341953245\">",
"    <span class=\"h2\">",
"     Renin mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the gene encoding renin have been identified in patients with ADIKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The full spectrum of clinical manifestations may not be fully appreciated, since fewer than 10 families have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341953129\">",
"    <span class=\"h3\">",
"     Renin genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renin (REN) gene is located on chromosome 1. Two REN gene mutations associated with ADIKD have been described, both of which mapped to the signal sequence of preprorenin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Mutations in this signal sequence disrupt the translocation of preprorenin into the endoplasmic reticulum of renin expressing cells.",
"   </p>",
"   <p>",
"    Because renin is essential for nephrogenesis, homozygous deletions of renin result in death during uterine development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341953136\">",
"    <span class=\"h3\">",
"     Pathophysiology of renin mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renin is expressed in multiple segments of the renal tubule, including the juxtaglomerular complex. In these cells, preprorenin is translocated into the endoplasmic reticulum, where it is converted to prorenin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/39\">",
"     39",
"    </a>",
"    ]. Some prorenin is secreted, while the remainder is targeted to lysozymes where it is further cleaved to active renin. Mutations that disrupt the signal sequence of prorenin prevent proper translocation to the endoplasmic reticulum, resulting in accumulation of preprorenin in the cytoplasm of renin producing cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accumulation of preprorenin in renal tubular cells leads to ultrastructural damage and apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In addition, renin levels in affected patients are low or low normal, although they may rise into the normal range when during periods of stress. The clinical manifestations of this condition presumably result from damage to renal tubular cells and low renin and angiotensin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341953331\">",
"    <span class=\"h2\">",
"     Mucin 1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with what has been called medullary cystic kidney disease type 1 (MCKD1) have mutations in the mucin 1 (MUC1) gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1572758\">",
"    <span class=\"h3\">",
"     Mucin 1 genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MUC1 gene is located on chromosome 1q21; previous to the discovery of MUC1 as the responsible gene, mapping of families with MCKD1 pointed to this region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/20-24,40,41\">",
"     20-24,40,41",
"    </a>",
"    ]. It appears that all affected individuals have a single cytosine insertion into one variable-number tandem repeat sequence within the MUC1 coding region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/20\">",
"     20",
"    </a>",
"    ]. This mutation results in an abnormal mucin 1 protein that localizes intracellularly in the loop of Henle, distal tubule, and collecting duct, and in the apical membrane of the collecting duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1572797\">",
"    <span class=\"h3\">",
"     Pathophysiology of mucin 1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of the renal findings is not understood. However, knockout studies in mice indicate that mucin 1 is a not an essential protein; therefore, it is possible that the MUC1 mutation in affected patients has a dominant negative or gain-of-function effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56166409\">",
"    <span class=\"h2\">",
"     ADIKD with unknown genetic linkage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several families have been identified with ADIKD that are not linked to the above genetic disorders. These patients may have other mutations in other genes or misdiagnosis may have occurred. Such families should be referred to academic medical centers for further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341953531\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18762362\">",
"    <span class=\"h2\">",
"     Overview of clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with ADIKD come to medical attention in one of three ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They are members of a family in which many individuals are already known to have kidney disease and early-onset gout. Younger members in the family either come forward for screening to determine if they are affected, or else come to attention when they become symptomatic with gout.",
"     </li>",
"     <li>",
"      They present in adolescence or early twenties with gout, a strong family history of kidney disease and gout, an elevated serum creatinine, and a bland urine sediment.",
"     </li>",
"     <li>",
"      They may be incidentally discovered to have chronic kidney disease (CKD) of unknown cause. The urine sediment is bland, and the family history is notable for many relatives with kidney disease and gout.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A presumptive diagnosis of ADIKD can be made in such patients; the diagnosis can be confirmed in most cases with genetic testing. (See",
"    <a class=\"local\" href=\"#H341953948\">",
"     'Diagnosis'",
"    </a>",
"    below.) De novo mutations rarely occur, resulting in CKD and early onset gout in the absence of a family history.",
"   </p>",
"   <p>",
"    Clinical manifestations differ somewhat depending upon the affected gene. Patients with mutations in the uromodulin (UMOD) or renin (REN) genes present with early onset hyperuricemia and gout. In contrast, patients with mutations in MUC1 present with an elevated serum creatinine; hyperuricemia and gout develop later during the course of disease.",
"   </p>",
"   <p>",
"    Regardless of the gene involved, patients with ADIKD develop CKD with a bland urine sediment. Microscopic hematuria is rare and an alternate cause should be sought. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations with UAKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with UMOD or REN gene mutations typically present during the teenage years with gout. In a series of 205 patients from 31 affected families with UAKD, 75 percent had hyperuricemia and 65 percent had gout, although these features were absent in some families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7\">",
"     7",
"    </a>",
"    ]. Asymptomatic hyperuricemia can often be detected during childhood if testing is performed early because of a positive family history.",
"   </p>",
"   <p>",
"    Gout and hyperuricemia are less common in females. However, serum uric acid concentrations in females are near the upper limit of the reference range from reporting laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/35\">",
"     35",
"    </a>",
"    ], and are higher than serum uric acid concentrations of similarly aged females.",
"   </p>",
"   <p>",
"    Affected individuals may also present with a mild elevation in serum creatinine, sometimes during the teenage years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/29\">",
"     29",
"    </a>",
"    ]. In the review of 205 patients mentioned above, 70 percent had CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7\">",
"     7",
"    </a>",
"    ]. The CKD progressed in 80 percent of these patients, with end-stage renal disease (ESRD) developing between the ages of 20 and 70 years. Similar observations were made in a series of 109 patients from 45 families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/26\">",
"     26",
"    </a>",
"    ]; the median age at ESRD onset was 54 years (range, 25 to 70 years). ESRD is inevitable in patients who survive long enough.",
"   </p>",
"   <p>",
"    Hypertension is uncommon in the early stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/2\">",
"     2",
"    </a>",
"    ]. The urinalysis is typically bland with minimal or no proteinuria. In patients who present with CKD rather than gout, most have marked hyperuricemia that is out of proportion to the degree of renal impairment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=see_link&amp;anchor=H5#H5\">",
"     \"Uric acid renal diseases\", section on 'Chronic urate nephropathy'",
"    </a>",
"    .) Mild urinary concentrating defects are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7\">",
"     7",
"    </a>",
"    ]. They can cause enuresis in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/4\">",
"     4",
"    </a>",
"    ], but are usually not clinically significant.",
"   </p>",
"   <p>",
"    The clinical manifestations are more severe in homozygotes from consanguineous families. These individuals have an earlier age of onset of hyperuricemia and progress more rapidly to ESRD than heterozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4683627\">",
"    <span class=\"h2\">",
"     Clinical manifestations with REN mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with UAKD, patients with REN gene mutations develop early onset gout and CKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, such patients are somewhat older when they present with gout (usually between ages 20 and 30 years), CKD progresses more slowly than it does with UAKD, and ESRD occurs later (after age 40). In addition, patients with REN gene mutations have clinical findings resulting from low renin and angiotensin levels that are",
"    <strong>",
"     not",
"    </strong>",
"    seen in patients with UAKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia, with low erythropoietin levels (ie, hypoproliferative), has been noted as early as one year of life. The anemia precedes the development of CKD and is thought to result from decreased levels of angiotensin, as has been noted in some patients taking angiotensin inhibitors. The anemia resolves with adolescence, implying that sex hormones may compensate for the effect of low angiotensin levels on erythrocyte production. The anemia recurs as CKD progresses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10857?source=see_link&amp;anchor=H264990867#H264990867\">",
"       \"Erythrocytosis following renal transplantation\", section on 'ACE inhibitors and ARBs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Affected individuals have low normal or normal blood pressure.",
"     </li>",
"     <li>",
"      Mild hyperkalemia may be present.",
"     </li>",
"     <li>",
"      Affected patients may be at increased risk for acute kidney injury in the setting of volume depletion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when nonsteroidal anti-inflammatory drugs are used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341953690\">",
"    <span class=\"h2\">",
"     Clinical manifestations of MUC1 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike patients with UAKD or REN gene mutations, patients with MCKD1 present with slowly progressive chronic kidney disease (not early onset gout and hyperuricemia), a bland urine sediment, and little or no proteinuria or hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Other clinical manifestations are uncommon, particularly early in the course of renal disease, as illustrated in a study of 72 affected individuals from six Cypriot families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of hypertension was related to renal function. In patients with a creatinine clearance 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or higher, 11 to 79",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , and less than 11",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , the prevalence of hypertension was 18, 48 percent, and 77 percent, respectively.",
"     </li>",
"     <li>",
"      Hyperuricemia and gout are",
"      <strong>",
"       not",
"      </strong>",
"      early findings, which helps to distinguish this disease from UAKD and REN gene mutations. However, as renal function declines, the risk of gout increases, but the increased risk is not out of proportion to the degree of renal dysfunction. In patients with a creatinine clearance of 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or higher, 11 to 79",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , and less than 11",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , the prevalence of hyperuricemia (defined as a serum uric acid above 7.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [416",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in males and 6.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [357",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      in females), was 12 percent, 45 percent, and 81 percent, respectively. Gout was uncommon, occurring in 7 percent, all of whom were males.",
"     </li>",
"     <li>",
"      The urine protein-to-creatinine ratio was less than 0.1 (normal) in two-thirds of affected patients and was never above 1.0. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Loss of urinary concentrating ability was not an early finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other manifestations associated with progressive chronic kidney disease (eg, anemia, renal osteodystrophy) occur at approximately the same rate as in other causes of CKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The course in affected families can be highly variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/24\">",
"     24",
"    </a>",
"    ]. In the study of 72 patients from six Cypriot families mentioned above, some had CKD noted during the teenage years with development of end-stage renal disease (ESRD) before age 30, while other patients had only moderate renal dysfunction into their 60s. Similar variability was noted in a study of five families in Finland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/22\">",
"     22",
"    </a>",
"    ]. In one family, symptoms began at 30 years of age or earlier and ESRD or death occurred between the ages of 25 and 33 years. In another family, ESRD or death occurred between the ages of 34 to 55 years. One carrier died at age 64 with no symptoms or signs of renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186295341\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary cysts may be apparent on various imaging studies, such as computerized tomography, intravenous pyelography, ultrasound, or magnetic resonance imaging enhanced by gadolinium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The prevalence of medullary cysts varies with the genetic mutation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In families with uromodulin-associated kidney disease (UAKD), the majority of affected members do",
"      <strong>",
"       not",
"      </strong>",
"      have medullary cysts on imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/29,35,44\">",
"       29,35,44",
"      </a>",
"      ], and there are some families with UAKD in which",
"      <strong>",
"       no",
"      </strong>",
"      affected members have cysts.",
"     </li>",
"     <li>",
"      In contrast, renal cysts are common in patients with MUC1 mutations. In the review of 72 Cypriot carriers, ultrasonography demonstrated cysts in 40 percent of tested carriers compared with 17 percent of normal controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/24\">",
"       24",
"      </a>",
"      ]. The cysts were bilateral in approximately 60 percent of cases. Most cysts were corticomedullary or medullary, but cortical cysts were also seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341953948\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ADIKD is suspected based upon clinical manifestations and the family history, and can be confirmed through genetic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341954262\">",
"    <span class=\"h2\">",
"     Presumptive clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive clinical diagnosis of ADIKD in a young individual presenting with gout",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic kidney disease (CKD) relies upon three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A strong family history of kidney disease in a pattern suggestive of autosomal dominant inheritance",
"     </li>",
"     <li>",
"      A strong family history of gout",
"     </li>",
"     <li>",
"      A bland urinary sediment with little or no proteinuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One or both of the first two factors may be missing in patients with spontaneous mutations, or if the family history is incomplete. In addition, a strong family history of gout may be absent in patients with a mutation in the MUC1 gene. It is important to include information about all family members, including aunts, uncles, and grandparents, and obtaining medical records from family members may be helpful.",
"   </p>",
"   <p>",
"    In patients with ADIKD, anemia beginning during childhood (before the onset of severe renal dysfunction) should raise suspicion for the presence of a REN gene mutation. Measurement of plasma renin and aldosterone is",
"    <strong>",
"     not",
"    </strong>",
"    usually helpful, since the levels of these hormones are highly variable depending upon volume status, posture, and stress. (See",
"    <a class=\"local\" href=\"#H4683627\">",
"     'Clinical manifestations with REN mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341954269\">",
"    <span class=\"h2\">",
"     Diagnostic confirmation with genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a clinical presentation consistent with ADIKD, a definitive diagnosis can be made in patients with UMOD, REN, and MUC1 mutations. Genetic testing of the UMOD gene is commercially available, whereas testing for REN gene and MUC1 gene mutations can only be performed at academic referral centers. Since UAKD is the most common form of ADIKD, testing for UMOD gene mutations should be performed first, unless there is a compelling reason to initially test the REN gene (eg, hypotension and juvenile anemia) or the MUC1 gene (eg, absence of hyperuricemia). (See",
"    <a class=\"local\" href=\"#H4683627\">",
"     'Clinical manifestations with REN mutations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H341953690\">",
"     'Clinical manifestations of MUC1 mutations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455655352\">",
"    <span class=\"h3\">",
"     Genetic testing of the UMOD gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutational analysis of the UMOD gene can be obtained for definitive diagnosis of UAKD. The test is available commercially from a number of companies, including Athena Diagnostics in Worcester, MA, which performs testing in the United States. Athena Diagnostics only analyzes exons 4 or 5 of the UMOD gene, sites at which almost all mutations occur. Although uncommon, mutations occurring in other exons will not be identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'UAKD genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An updated list of laboratories that perform uromodulin testing is available at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341954304\">",
"    <span class=\"h3\">",
"     Genetic testing of the REN gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike UMOD, mutational analysis of the REN gene is not commercially available. REN genetic testing is performed on an investigational basis at Wake Forest University School of Medicine (ableyer@wfubmc.edu), at the Charles University in Prague (Stanislav.Kmoch@lf1.cuni.cz), and by other academic medical centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341954349\">",
"    <span class=\"h3\">",
"     Genetic testing of the MUC1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;If MCKD1 is diagnosed clinically or is strongly suspected, there may be benefit from referral of the patient and family to an academic center for linkage studies (ableyer@wfubmc.edu, in Winston-Salem, North Carolina, or Stanislav.Kmoch@lf1.cuni.cz, at the Charles University in Prague). A definitive diagnosis of MCKD1 can be made if the disease causing mutation is found in MUC1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455654786\">",
"    <span class=\"h2\">",
"     Supportive but rarely used clinical tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not definitive, other clinical data may support the diagnosis of ADIKD. These include a low fractional excretion of uric acid, and the presence of tubular cysts with tubulointerstitial fibrosis on renal biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455655555\">",
"    <span class=\"h3\">",
"     Fractional excretion of uric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with UAKD or a REN gene mutation, but not patients with MUC1 mutations, should have hyperuricemia and a low fractional excretion of uric acid (ie, they should be an underexcretor) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/10,11,35,36,45\">",
"     10,11,35,36,45",
"    </a>",
"    ]. The fractional excretion of uric acid (FEUA) can be calculated from a random urine specimen using the same formula used to calculate the fractional excretion of sodium, substituting uric acid for sodium using either standard units (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?25/13/25809?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or SI units (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?24/28/25025?source=see_link\">",
"     calculator 2",
"    </a>",
"    ): &nbsp;",
"   </p>",
"   <p>",
"    FEUA &nbsp;= &nbsp;(urine uric acid concentration &nbsp;x &nbsp;serum creatinine) &nbsp;&divide; &nbsp;(urine creatinine concentration &nbsp;x &nbsp;serum uric acid)",
"   </p>",
"   <p>",
"    Underexcretion is defined as an FEUA less than 6 percent and is often below 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/35\">",
"     35",
"    </a>",
"    ]. Normal values in healthy adults are 8&plusmn;3 percent in males and 13&plusmn;3 percent in females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/45\">",
"     45",
"    </a>",
"    ]. The normal fractional excretion of uric acid in healthy children is even higher (18&plusmn;5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One caveat is that the fractional excretion of uric acid and other solutes, such as sodium, increases as renal function worsens (ie, as the filtered load falls). The expected values for FEUA cited above only apply to patients with a glomerular filtration rate above 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/35,46\">",
"     35,46",
"    </a>",
"    ]. Higher values would be seen at lower filtration rates. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455655562\">",
"    <span class=\"h3\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsy in patients with ADIKD reveals tubulointerstitial fibrosis and other nonspecific findings. With the availability of mutational analysis, and because renal biopsy cannot make a specific diagnosis of ADIKD, we do",
"    <strong>",
"     not",
"    </strong>",
"    perform a renal biopsy as part of the routine diagnostic work-up of patients with suspected ADIKD.",
"   </p>",
"   <p>",
"    However, renal biopsy is occasionally performed to evaluate CKD in patients in whom ADIKD has not been considered. In these patients, the typical finding is diffuse tubulointerstitial fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Tubular dilatations, which can enlarge to tubular cysts, may be present, but uric acid crystals are not seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/10\">",
"     10",
"    </a>",
"    ]. Glomerulocystic changes have been identified in two families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/9,47\">",
"     9,47",
"    </a>",
"    ], but they are not typical of ADIKD.",
"   </p>",
"   <p>",
"    These pathologic changes are",
"    <strong>",
"     not",
"    </strong>",
"    pathognomonic, and pathologists will rarely make the diagnosis based solely upon the biopsy results. Immunofluorescence microscopy with antibodies to uromodulin can be performed, which will demonstrate abnormal deposition of uromodulin in tubular cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/29\">",
"     29",
"    </a>",
"    ]. This test is not routinely performed unless the diagnosis of ADIKD is considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341954552\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In young individuals presenting with gout, the differential diagnosis includes other potential causes of early onset hyperuricemia, such as obesity, psoriasis, or the use of thiazide diuretics. These diagnoses are usually obvious from the clinical evaluation. A strong family history of gout and renal failure would suggest UMOD or REN mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link&amp;anchor=H13#H13\">",
"     \"Health hazards associated with obesity in adults\", section on 'Gout'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In young patients presenting with unexplained CKD, the urinalysis is helpful in distinguishing ADIKD from other forms of inherited kidney disease. The absence of hematuria or significant proteinuria excludes other genetic glomerular diseases, such as Alport syndrome (usually X-linked with frequent hematuria and proteinuria) or familial focal segmental glomerulosclerosis (nephrotic syndrome present). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H23#H23\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Genetic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patient presents with medullary cysts by an imaging study, the differential diagnosis includes other inherited cystic diseases that often present in childhood. Acquired cystic diseases, often associated with CKD, can be distinguished from ADIKD because a family history of cysts, CKD, and gout will usually be absent. (See",
"    <a class=\"local\" href=\"#H186295341\">",
"     'Imaging'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2712?source=see_link\">",
"     \"Renal cystic diseases in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23638?source=see_link\">",
"     \"Acquired cystic disease of the kidney in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H341954671\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of ADIKD includes management of hyperuricemia and gout, and management of progressive CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455655913\">",
"    <span class=\"h2\">",
"     Management of hyperuricemia and gout",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known UMOD and REN gene mutations who develop gout should be treated with a xanthine oxidase inhibitor, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/35\">",
"     35",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29668?source=see_link\">",
"     Febuxostat",
"    </a>",
"    should be considered in patients who do not tolerate allopurinol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36266?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of recurrent gout\", section on 'Xanthine oxidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue is whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    might slow the rate of progression of the CKD. As mentioned above, the hyperuricemia in uromodulin-associated kidney disease (UAKD) results from underexcretion, not overproduction as in acute urate nephropathy. In addition, uric acid crystals have not been identified when renal biopsy is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, it is not known whether uric acid plays a role in the pathogenesis of CKD in patients with UAKD.",
"   </p>",
"   <p>",
"    Several observational studies have examined the association between uric acid lowering drugs and progression of CKD in patients with UAKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/10,35,48-50\">",
"     10,35,48-50",
"    </a>",
"    ]. No randomized trials have been published and there is no useful information on the much less common renin and mucin 1 mutations.",
"   </p>",
"   <p>",
"    The best data come from a report of 27 patients with familial juvenile hyperuricemic nephropathy (now called UAKD) in which the diagnosis was made on clinical grounds before the advent of uromodulin gene testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/48\">",
"     48",
"    </a>",
"    ]. All were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    and the efficacy of therapy appeared to depend upon when the drug was initiated. Progression to end-stage renal disease within 2 to 10 years occurred in five of six patients in whom allopurinol was initiated when the serum creatinine was greater than 2.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    In contrast, no patient who started allopurinol therapy when the serum creatinine was less than 2.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    progressed to ESRD during 10 to 34 years of follow-up. In eight of these patients without CKD at the time they initiated allopurinol, renal function remained unchanged for up to 20 years.",
"   </p>",
"   <p>",
"    There is also weak evidence in two patients that benzbromarone, a uricosuric agent, might slow progression of CKD in patients with UAKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/50\">",
"     50",
"    </a>",
"    ]. However, it is currently unavailable in many countries.",
"   </p>",
"   <p>",
"    Based upon the available data, we suggest the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    in patients with ADIKD who have symptomatic gout. Before initiating allopurinol solely for the prevention of CKD progression, however, the known risks, potential benefits, and alternatives should be discussed with the patients and family members. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     \"Allopurinol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36266?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of recurrent gout\", section on 'Xanthine oxidase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Young men who have the disease are highly likely to develop gout, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    should be strongly considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33721/abstract/35\">",
"     35",
"    </a>",
"    ]. For the asymptomatic younger women, the minimal potential risk and the potential benefit should be discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H455656093\">",
"    <span class=\"h2\">",
"     Management of CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with ADIKD are normotensive and do not have much proteinuria. As a result, they are less likely to be treated with angiotensin inhibitors, which can slow the progression of proteinuric chronic kidney disease. There is no evidence that angiotensin inhibitors slow the progression of CKD in patients with ADIKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of other manifestations of CKD, such as anemia and hyperphosphatemia, and the treatment of end-stage renal disease is similar to that in patients without ADIKD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ADIKD are good candidates for renal transplantation since the disease does not recur in the transplanted kidney. Family members of patients with UAKD, REN, or MUC1 gene mutations should undergo genetic testing prior to donating a kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H993284\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION AND CORRESPONDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author is interested in studying the clinical and genetic characteristics of individuals with these disorders and would be willing to discuss potential cases with the reader. Author e-mail: ableyer@wfubmc.edu.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H997405\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant interstitial kidney disease (ADIKD) is a rare genetic disorder. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ADIKD has been variably known as medullary cystic kidney disease (MCKD), familial juvenile hyperuricemic nephropathy, and uromodulin associated kidney disease (UAKD). The most commonly used term, MCKD, is a misnomer since most affected patients do",
"      <strong>",
"       not",
"      </strong>",
"      have medullary cysts. (See",
"      <a class=\"local\" href=\"#H111033540\">",
"       'Terminology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classification of ADIKD is based upon the underlying genetic mutation. There are at least four types of ADIKD (see",
"      <a class=\"local\" href=\"#H111033564\">",
"       'Classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      UAKD is caused by mutations in the UMOD gene, which encodes uromodulin (Tamm Horsfall protein). UAKD constitutes the majority of cases of ADIKD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Uromodulin-associated kidney disease (UAKD)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations in the REN gene, which encodes renin, have been identified as causes of ADIKD. (See",
"      <a class=\"local\" href=\"#H341953245\">",
"       'Renin mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations in the MUC1 gene, which encodes mucin 1, have been described in some families. This form of ADIKD has often been referred to as medullary cystic kidney disease type 1 (MCKD1). (See",
"      <a class=\"local\" href=\"#H341953331\">",
"       'Mucin 1 mutations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mutations in other, as yet unidentified genes. Some families with ADIKD have been identified that do not to have mutations in the UMOD, REN, or MUC1 genes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ADIKD, regardless of the gene involved, develop chronic kidney disease with a bland urine sediment. Hyperuricemia and gout can occur but the age at onset varies with the genetic mutation. As examples, the onset hyperuricemia occurs early in patients with mutation in the uromodulin or renin gene and occurs late or not at all in patients with mutations in MUC1. (See",
"      <a class=\"local\" href=\"#H341953531\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A presumptive clinical diagnosis of ADIKD in a young individual presenting with gout",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CKD relies upon three factors (see",
"      <a class=\"local\" href=\"#H341954262\">",
"       'Presumptive clinical diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A strong family history of kidney disease in a pattern suggestive of autosomal dominant inheritance",
"     </li>",
"     <li>",
"      A strong family history of gout, although this will be absent in patients whose mutation is in MUC1",
"     </li>",
"     <li>",
"      A bland urinary sediment with little or no proteinuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A definitive diagnosis of ADIKD can be made in many cases by genetic testing. Genetic testing of the UMOD gene is commercially available. Testing for the REN gene and the MUC1 gene can be performed at academic referral centers. Since UAKD is the most common form of ADIKD, testing for UMOD gene mutations should be performed first, unless there is a compelling reason to initially test for the REN or MUC1 genes. (See",
"      <a class=\"local\" href=\"#H341954269\">",
"       'Diagnostic confirmation with genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have gout are usually treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      . It is unclear if lowering uric acid levels or initiating therapy with angiotensin inhibitors prevents the progression of CKD. The management of CKD in patients with ADIKD is similar to that in patients with other causes of CKD. (See",
"      <a class=\"local\" href=\"#H341954671\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The author is interested in studying the clinical and genetic characteristics of individuals with these disorders and would be willing to discuss potential cases with the reader. Author e-mail: ableyer@wfubmc.edu.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/1\">",
"      Hildebrandt F, Omram H. New insights: nephronophthisis-medullary cystic kidney disease. Pediatr Nephrol 2001; 16:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/2\">",
"      Wolf MT, Beck BB, Zaucke F, et al. The Uromodulin C744G mutation causes MCKD2 and FJHN in children and adults and may be due to a possible founder effect. Kidney Int 2007; 71:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/3\">",
"      Kudo E, Kamatani N, Tezuka O, et al. Familial juvenile hyperuricemic nephropathy: detection of mutations in the uromodulin gene in five Japanese families. Kidney Int 2004; 65:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/4\">",
"      Hart TC, Gorry MC, Hart PS, et al. Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 2002; 39:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/5\">",
"      Dahan K, Devuyst O, Smaers M, et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 2003; 14:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/6\">",
"      Dahan K, Fuchshuber A, Adamis S, et al. Familial juvenile hyperuricemic nephropathy and autosomal dominant medullary cystic kidney disease type 2: two facets of the same disease? J Am Soc Nephrol 2001; 12:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/7\">",
"      Scolari F, Caridi G, Rampoldi L, et al. Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 2004; 44:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/8\">",
"      Hodanov&aacute; K, Majewski J, Kublov&aacute; M, et al. Mapping of a new candidate locus for uromodulin-associated kidney disease (UAKD) to chromosome 1q41. Kidney Int 2005; 68:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/9\">",
"      Lens XM, Banet JF, Outeda P, Barrio-Luc&iacute;a V. A novel pattern of mutation in uromodulin disorders: autosomal dominant medullary cystic kidney disease type 2, familial juvenile hyperuricemic nephropathy, and autosomal dominant glomerulocystic kidney disease. Am J Kidney Dis 2005; 46:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/10\">",
"      Puig JG, Miranda ME, Mateos FA, et al. Hereditary nephropathy associated with hyperuricemia and gout. Arch Intern Med 1993; 153:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/11\">",
"      Turner JJ, Stacey JM, Harding B, et al. UROMODULIN mutations cause familial juvenile hyperuricemic nephropathy. J Clin Endocrinol Metab 2003; 88:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/12\">",
"      Wolf MT, Mucha BE, Attanasio M, et al. Mutations of the Uromodulin gene in MCKD type 2 patients cluster in exon 4, which encodes three EGF-like domains. Kidney Int 2003; 64:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/13\">",
"      Stibrkov&aacute; B, Majewski J, Hodanov&aacute; K, et al. Familial juvenile hyperuricaemic nephropathy (FJHN): linkage analysis in 15 families, physical and transcriptional characterisation of the FJHN critical region on chromosome 16p11.2 and the analysis of seven candidate genes. Eur J Hum Genet 2003; 11:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/14\">",
"      Hateboer N, Gumbs C, Teare MD, et al. Confirmation of a gene locus for medullary cystic kidney disease (MCKD2) on chromosome 16p12. Kidney Int 2001; 60:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/15\">",
"      Tinschert S, Ruf N, Bernascone I, et al. Functional consequences of a novel uromodulin mutation in a family with familial juvenile hyperuricaemic nephropathy. Nephrol Dial Transplant 2004; 19:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/16\">",
"      K&ouml;ttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 2009; 41:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/17\">",
"      Rezende-Lima W, Parreira KS, Garc&iacute;a-Gonz&aacute;lez M, et al. Homozygosity for uromodulin disorders: FJHN and MCKD-type 2. Kidney Int 2004; 66:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/18\">",
"      Zivn&aacute; M, Hlkov&aacute; H, Matignon M, et al. Dominant renin gene mutations associated with early-onset hyperuricemia, anemia, and chronic kidney failure. Am J Hum Genet 2009; 85:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/19\">",
"      Bleyer AJ, Zivn&aacute; M, Hulkov&aacute; H, et al. Clinical and molecular characterization of a family with a dominant renin gene mutation and response to treatment with fludrocortisone. Clin Nephrol 2010; 74:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/20\">",
"      Kirby A, Gnirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat Genet 2013; 45:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/21\">",
"      Kiser RL, Wolf MT, Martin JL, et al. Medullary cystic kidney disease type 1 in a large Native-American kindred. Am J Kidney Dis 2004; 44:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/22\">",
"      Auranen M, Ala-Mello S, Turunen JA, J&auml;rvel&auml; I. Further evidence for linkage of autosomal-dominant medullary cystic kidney disease on chromosome 1q21. Kidney Int 2001; 60:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/23\">",
"      Wolf MT, Mucha BE, Hennies HC, et al. Medullary cystic kidney disease type 1: mutational analysis in 37 genes based on haplotype sharing. Hum Genet 2006; 119:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/24\">",
"      Stavrou C, Koptides M, Tombazos C, et al. Autosomal-dominant medullary cystic kidney disease type 1: clinical and molecular findings in six large Cypriot families. Kidney Int 2002; 62:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/25\">",
"      Piret SE, Danoy P, Dahan K, et al. Genome-wide study of familial juvenile hyperuricaemic (gouty) nephropathy (FJHN) indicates a new locus, FJHN3, linked to chromosome 2p22.1-p21. Hum Genet 2011; 129:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/26\">",
"      Boll&eacute;e G, Dahan K, Flamant M, et al. Phenotype and outcome in hereditary tubulointerstitial nephritis secondary to UMOD mutations. Clin J Am Soc Nephrol 2011; 6:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/27\">",
"      Choi SW, Ryu OH, Choi SJ, et al. Mutant tamm-horsfall glycoprotein accumulation in endoplasmic reticulum induces apoptosis reversed by colchicine and sodium 4-phenylbutyrate. J Am Soc Nephrol 2005; 16:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/28\">",
"      Rampoldi L, Caridi G, Santon D, et al. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 2003; 12:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/29\">",
"      Bleyer AJ, Hart TC, Willingham MC, et al. Clinico-pathologic findings in medullary cystic kidney disease type 2. Pediatr Nephrol 2005; 20:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/30\">",
"      Hoyer JR, Sisson SP, Vernier RL. Tamm-Horsfall glycoprotein: ultrastructural immunoperoxidase localization in rat kidney. Lab Invest 1979; 41:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/31\">",
"      Serafini-Cessi F, Malagolini N, Cavallone D. Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 2003; 42:658.",
"     </a>",
"    </li>",
"    <li>",
"     Mutig K, Kahl T, Saritas T, et al. Kidney Na,K,2Cl-Cotransporter (NKCC2) is regulated by Tamm-Horsfall Protein (THP).  American Society of Nephrology Annual Meeting, Abstract FC 134, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/33\">",
"      Renigunta A, Renigunta V, Saritas T, et al. Tamm-Horsfall glycoprotein interacts with renal outer medullary potassium channel ROMK2 and regulates its function. J Biol Chem 2011; 286:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/34\">",
"      Bleyer AJ, Hart TC, Shihabi Z, et al. Mutations in the uromodulin gene decrease urinary excretion of Tamm-Horsfall protein. Kidney Int 2004; 66:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/35\">",
"      Bleyer AJ, Woodard AS, Shihabi Z, et al. Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. Kidney Int 2003; 64:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/36\">",
"      Cameron JS, Simmonds HA. Hereditary hyperuricemia and renal disease. Semin Nephrol 2005; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/37\">",
"      Bates JM, Raffi HM, Prasadan K, et al. Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 2004; 65:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/38\">",
"      Gubler MC, Antignac C. Renin-angiotensin system in kidney development: renal tubular dysgenesis. Kidney Int 2010; 77:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/39\">",
"      Dzau VJ, Pratt RE, Paul M, Nakamura N. Molecular studies of human renin synthesis and gene expression. Cardiovasc Drugs Ther 1988; 2:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/40\">",
"      Christodoulou K, Tsingis M, Stavrou C, et al. Chromosome 1 localization of a gene for autosomal dominant medullary cystic kidney disease. Hum Mol Genet 1998; 7:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/41\">",
"      Wolf MT, Karle SM, Schwarz S, et al. Refinement of the critical region for MCKD1 by detection of transcontinental haplotype sharing. Kidney Int 2003; 64:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/42\">",
"      Katabathina VS, Kota G, Dasyam AK, et al. Adult renal cystic disease: a genetic, biological, and developmental primer. Radiographics 2010; 30:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/43\">",
"      Meier P, Farres MT, Mougenot B, et al. Imaging medullary cystic kidney disease with magnetic resonance. Am J Kidney Dis 2003; 42:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/44\">",
"      Neumann HP, Z&auml;uner I, Strahm B, et al. Late occurrence of cysts in autosomal dominant medullary cystic kidney disease. Nephrol Dial Transplant 1997; 12:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/45\">",
"      McBride MB, Rigden S, Haycock GB, et al. Presymptomatic detection of familial juvenile hyperuricaemic nephropathy in children. Pediatr Nephrol 1998; 12:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/46\">",
"      Danovitch GM. Uric acid transport in renal failure. A review. Nephron 1972; 9:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/47\">",
"      Gusmano R, Caridi G, Marini M, et al. Glomerulocystic kidney disease in a family. Nephrol Dial Transplant 2002; 17:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/48\">",
"      Fairbanks LD, Cameron JS, Venkat-Raman G, et al. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. QJM 2002; 95:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/49\">",
"      McBride MB, Simmonds HA, Ogg CS, et al. Efficacy of allopurinol in ameliorating the progressive renal disease in familial juvenile hyperuricaemic nephropathy (FJHN). A six-year update. Adv Exp Med Biol 1998; 431:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33721/abstract/50\">",
"      Lhotta K. Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone? Kidney Int 2003; 64:1920.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1685 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33721=[""].join("\n");
var outline_f32_59_33721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H997405\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111033540\">",
"      TERMINOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H111033564\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341952946\">",
"      GENETICS AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Uromodulin-associated kidney disease (UAKD)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - UAKD genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - UAKD pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341953245\">",
"      Renin mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341953129\">",
"      - Renin genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341953136\">",
"      - Pathophysiology of renin mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341953331\">",
"      Mucin 1 mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1572758\">",
"      - Mucin 1 genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1572797\">",
"      - Pathophysiology of mucin 1 mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56166409\">",
"      ADIKD with unknown genetic linkage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341953531\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18762362\">",
"      Overview of clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations with UAKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4683627\">",
"      Clinical manifestations with REN mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341953690\">",
"      Clinical manifestations of MUC1 mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186295341\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341953948\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341954262\">",
"      Presumptive clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H341954269\">",
"      Diagnostic confirmation with genetic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455655352\">",
"      - Genetic testing of the UMOD gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341954304\">",
"      - Genetic testing of the REN gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H341954349\">",
"      - Genetic testing of the MUC1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455654786\">",
"      Supportive but rarely used clinical tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455655555\">",
"      - Fractional excretion of uric acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H455655562\">",
"      - Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341954552\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H341954671\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455655913\">",
"      Management of hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H455656093\">",
"      Management of CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H993284\">",
"      ADDITIONAL INFORMATION AND CORRESPONDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H997405\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1685|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/62/31725\" title=\"figure 1\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?25/13/25809?source=related_link\" title=\"calculator 1\">",
"      Calculator: Fractional excretion of sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?24/28/25025?source=related_link\" title=\"calculator 2\">",
"      Calculator: Fractional excretion of sodium (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23638?source=related_link\">",
"      Acquired cystic disease of the kidney in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=related_link\">",
"      Allopurinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10857?source=related_link\">",
"      Erythrocytosis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/56/10120?source=related_link\">",
"      Genetics and pathogenesis of nephronophthisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2712?source=related_link\">",
"      Renal cystic diseases in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_59_33722="Focal segmental glomerulosclerosis in the transplanted kidney";
var content_f32_59_33722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Focal segmental glomerulosclerosis in the transplanted kidney",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Nada Alachkar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Christopher H Kwoh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/59/33722/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/59/33722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal segmental glomerulosclerosis (FSGS) is a histologic pattern of injury in the kidney that may have multiple different etiologies, including genetic diseases, infection, toxins and obesity, as well as previous injury resulting in hyperfiltration of remaining viable nephrons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary idiopathic FSGS, which occurs in the absence of a known etiology, commonly progresses to end-stage renal disease. When transplantation is performed, primary idiopathic FSGS may recur in the renal allograft.",
"   </p>",
"   <p>",
"    An overview of FSGS in the renal allograft is presented in this topic review. The pathogenesis and treatment of FSGS in the native kidney are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1110880582\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;FSGS in the allograft may be recurrent or de novo. Both recurrent and de novo FSGS may be primary idiopathic or related to known causes, such as infection, toxin exposure, genetic mutation or obesity. In addition, FSGS may develop as a result of hyperfiltration injury related to loss of functioning kidney parenchyma; this form of FSGS is traditionally called secondary FSGS. In this review, FSGS related to a known cause other than hyperfiltration is referred to as primary non-idiopathic FSGS. FSGS that is without a known cause is called primary idiopathic FSGS. The term secondary FSGS is reserved for FSGS that is due to hyperfiltration injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1045081412\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of recurrence of primary idiopathic FSGS is difficult to ascertain since it is often not clear whether the patient had primary idiopathic FSGS or FSGS related to other causes as the initial cause of end-stage renal disease (ESRD). Although the reported FSGS recurrence rate averages about 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/1-10\">",
"     1-10",
"    </a>",
"    ], it is likely that some of the patients in these studies had FSGS due to a toxin, viral infection or hyperfiltration injury that would not be expected to recur in the transplant. Thus, the rate of recurrence among patients with primary idiopathic FSGS may be higher than 30 percent. There is, for example, a subgroup in which the disease recurs in about one-half of cases. These patients, who almost certainly have primary idiopathic FSGS, tend to be less than 20 years of age and to have had a rapid clinical course, with the interval from diagnosis of FSGS to end-stage renal disease being less than three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/1,4,11,12\">",
"     1,4,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, among patients with FSGS as a cause of ESRD in the native kidney, allograft loss due to recurrent FSGS is not uncommon. Two large studies in adults examined the incidence of graft loss due to recurrence of FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated 221 renal transplant recipients in the Australia and New Zealand Transplant Registry with a history of end-stage renal disease due to biopsy-proven FSGS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/13\">",
"       13",
"      </a>",
"      ]. The incidence of allograft loss at 10 years due to recurrent disease was 12.7 percent (95% CI 7.3-21.6).",
"     </li>",
"     <li>",
"      Another report analyzed 3861 recipients of solitary kidney transplants with a primary diagnosis of FSGS from the United States Renal Data System (USRDS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/8\">",
"       8",
"      </a>",
"      ]. The reported rate of graft loss due to recurrence was only 2.6 percent with a mean follow-up of three years. However, 8 percent of patients were lost to follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of allograft loss due to recurrent FSGS has also been evaluated in children. A study based upon the North American Pediatric Renal Transplant Cooperative Study database (NAPRTCS) compared transplant outcomes of 752 pediatric patients with FSGS with 5732 control patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/14\">",
"     14",
"    </a>",
"    ]. In this analysis, graft loss from recurrent FSGS among children was 6.1 percent at five years.",
"   </p>",
"   <p>",
"    These studies underestimate the overall risk of recurrence since not all patients who have recurrent disease have allograft failure. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Five histologic patterns of FSGS have been recognized, which are associated with different clinical manifestations and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Histologic variants'",
"    </a>",
"    .) It is not clear whether the histologic subtype observed in recurrent FSGS is generally the same subtype as that observed in the native kidney. Two studies have looked at this with different results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one multicenter study that included 21 cases of recurrent FSGS in 19 patients, 81 percent had recurrence of the same histologic subtype as was present in the native kidney [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a later study from France of 77 patients, the histologic subtype in the native kidney did not predict that which recurred in the allograft [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Differences in the study populations (adult versus pediatric) may explain the discrepant results between studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/18\">",
"     18",
"    </a>",
"    ]. The timing of the biopsy, which was much later in the French study cited above, may also have contributed to the different results since the FSGS lesion may evolve over time.",
"   </p>",
"   <p>",
"    De novo FSGS may also occur in the transplanted kidney among patients who did not have FSGS as a cause of ESRD in the native kidney. The incidence of this is difficult to estimate since the cause of ESRD in the native kidney is unknown among many transplant recipients. In one study of 4,913 transplant recipients, 57 patients developed biopsy-demonstrated FSGS in the transplanted kidney at a follow-up of 1.8 years; of these, 30 (53 percent) had known FSGS in the native kidney and 27 (47 percent) did not have a renal biopsy of the native kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/19\">",
"     19",
"    </a>",
"    ]. From these data one can estimate that new FSGS develops in less than 0.6 percent of allografts, since at least some of the patients in this group probably had undiagnosed FSGS in the native kidney. However because of the relatively limited follow-up (less than two years) this study underestimated the rate of incidence of new onset secondary FSGS related to hyperfiltration injury which generally takes longer to develop. (See",
"    <a class=\"local\" href=\"#H195632586\">",
"     'De novo primary non-idiopathic FSGS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1107666570\">",
"    <span class=\"h2\">",
"     Risk factors for recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major risk factors for recurrence of FSGS include childhood onset of initial disease, rapid progression of initial disease, and a history of recurrence in a prior allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In the United States, white recipients of African American kidneys may be at particularly high risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/8\">",
"     8",
"    </a>",
"    ]. On the other hand, blacks appear to represent a lower risk group in which recurrence is less frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As described above, five histologic patterns of FSGS have been recognized, which are associated with different clinical manifestations and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Histologic variants'",
"    </a>",
"    .) However, the histologic subtype observed in the native kidney does not predict the risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A family history of FSGS generally predicts a low risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In 48 kidney transplants from the Duke registry of familial FSGS, which includes patients with FSGS and one family member with either biopsy-proven FSGS or high-grade proteinuria, only one post-transplant recurrence of FSGS was reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of recurrence of familial FSGS may depend upon the specific mutation. Recurrent disease has been reported among patients with podocin mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/23-28\">",
"     23-28",
"    </a>",
"    ], and in one patient with a TRPC6 mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an Italian study of 53 patients with apparently sporadic steroid-resistant nephrotic syndrome who had undergone renal transplantation, mutations in the gene for podocin were found in 13 patients, of whom nine had homozygous or compound heterozygous defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/25\">",
"       25",
"      </a>",
"      ]. Two patients had post-transplant recurrence with clinical features and response to therapy that were indistinguishable from those with recurrence of non-genetic forms of FSGS.",
"     </li>",
"     <li>",
"      Among 53 patients identified from the European FSGS Transplantation Study Group, who received at least one renal allograft, 11 had homozygous or compound heterozygous podocin mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/28\">",
"       28",
"      </a>",
"      ]. None of the patients with podocin mutations had recurrence compared to 45 percent of those without mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies have also found low recurrence rates among patients with homozygous or compound heterozygous podocin mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of these studies are complicated since, with non-familial cases, it is difficult to identify which alterations in podocin are disease-causing mutations and which are innocent variants. In addition, most cases of post-transplant recurrence with podocin (NPHS2) mutations are still responsive to aggressive therapy, despite being resistant to therapy pretransplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/24\">",
"     24",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The significance of heterozygous podocin mutations in the risk of post-transplant recurrence has not been extensively studied. One study reported recurrence in two of five patients (40 percent), a figure similar to sporadic primary idiopathic FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/24\">",
"     24",
"    </a>",
"    ]. In the international cohort study cited above however, four patients had solitary heterozygous mutations with no recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have questioned whether various immunosuppressive regimens have altered the risk of recurrence and in particular whether the use of calcineurin inhibitors has decreased the risk of recurrent FSGS in the modern era of transplantation. Most studies suggest that the choice of immunosuppressive therapies has no effect on the chances of recurrence. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of renal transplant recipients performed at a single center between December 1999 and March 2007, approximately 23 percent (15 out of 66) of patients with biopsy-proven FSGS had recurrence at a mean of 5.3 months after transplantation, which is not significantly different from the incidence cited in older series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 16 children with biopsy-proven FSGS who received allografts between 1985 and 2007, 9 (56 percent) had recurrent FSGS within a mean of 9.6 days after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/30\">",
"       30",
"      </a>",
"      ]. There was no difference in the induction or subsequent immunosuppressive therapies used among those who did and did not develop recurrent disease.",
"     </li>",
"     <li>",
"      A retrospective review of 4500 transplant recipients with ESRD from FSGS who were registered in the",
"      <span class=\"nowrap\">",
"       OPTN/UNOS",
"      </span>",
"      database from 1988 to 2007, demonstrated no significant difference in graft loss due to recurrent FSGS between those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      based regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However one retrospective study suggested that the rate of recurrent glomerulonephritis, including FSGS, was lower in patients who received induction therapy with thymoglobulin (polyclonal rabbit-antithymocyte globulin) compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    and an interleukin 2 receptor antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/32\">",
"     32",
"    </a>",
"    ]. A similar trend that was not statistically significant was also observed in the subset of patients who had FSGS. Randomized trials are necessary to confirm this observation.",
"   </p>",
"   <p>",
"    Although these are insufficient data upon which to base the choice of induction therapy, we generally administer thymoglobulin to most patients undergoing kidney transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link&amp;anchor=H5#H5\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\", section on 'Polyclonal antibodies'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1173618337\">",
"    <span class=\"h3\">",
"     Urinary apolipoprotein A-1 (ApoA-1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased urinary concentration of apoproteinA-1 (ApoA-1), a component of high density lipoprotein (HDL) has been associated with recurrent idiopathic FSGS among transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/33\">",
"     33",
"    </a>",
"    ]. Increased urinary ApoA-1 was initially detected by proteomic analysis in 8 transplant recipients with recurrent FSGS but not in 27 transplant recipients who had nonrecurrent FSGS in the native kidney. Patients with familial FSGS were excluded from the analysis. In an independent validation study, ApoA-1 was detected in 5 of 6 transplant recipients with recurrent FSGS but in only 1 of 34 transplant recipients with nonrecurrent FSGS in the native kidney. Increased ApoA-1 was also not detected in any of 14 transplant recipients with familial FSGS or in any of 30 patients with proteinuria unrelated to FSGS (including 17 transplant recipients and 13 nontransplant recipients). ApoA-1 may provide a useful biomarker for recurrent FSGS although further investigation is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519568810\">",
"    <span class=\"h2\">",
"     Recurrent primary idiopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent primary idiopathic FSGS is likely due to a circulating factor or the absence of a normally present factor in plasma, with either resulting in toxicity to the glomerular capillary wall. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reports support this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/1,34-40\">",
"     1,34-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum from some patients with FSGS increases the permeability of isolated glomeruli to albumin. The ability of pretransplant serum to increase",
"      <em>",
"       in vitro",
"      </em>",
"      glomerular permeability may predict FSGS recurrence after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. As an example, in one study, the incidence of recurrence was 86 percent (6 of 7) when glomerular permeability to albumin was substantially increased by exposure to patient serum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/34\">",
"       34",
"      </a>",
"      ]. By contrast, the incidence of recurrence was only 17 percent (4 of 19) among patients whose serum did not increase",
"      <em>",
"       in vitro",
"      </em>",
"      glomerular permeability.",
"      <br/>",
"      <br/>",
"      Similar findings were observed in a series of 25 children transplanted for FSGS; recurrence occurred in 85 percent (11 of 13) of those whose serum produced increased glomerular permeability compared with 33 percent (4 of 12) of those with a negative result [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/35\">",
"       35",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the first study, serum from transplanted patients with FSGS who did not have recurrence did not increase glomerular permeability suggesting that the permeability factor may be specific to only certain types of FSGS that are more likely to recur in the transplanted kidney [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of a regenerating protein adsorption column or plasma exchange can reduce protein excretion in a subgroup of patients with recurrent FSGS (",
"      <a class=\"graphic graphic_figure graphicRef51857 \" href=\"mobipreview.htm?39/6/40045\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/36\">",
"       36",
"      </a>",
"      ]. The factor that is removed increased protein excretion when injected into rats.",
"     </li>",
"     <li>",
"      More prolonged remissions have been achieved using standard plasmapheresis that is initiated promptly after the onset of proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/37\">",
"       37",
"      </a>",
"      ] or the combination of plasmapheresis and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indirect support for a circulating recipient factor is provided by a case report in which a kidney transplant recipient developed early (ie, within two days of transplant surgery) recurrent FSGS with marked proteinuria and foot process effacement on biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/41\">",
"       41",
"      </a>",
"      ]. Upon removal of the kidney and re-transplantation into a second recipient, there was almost complete resolution of proteinuria and reversal of histologic lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The identity of the circulating permeability factor is not known with certainty, although the serum soluble urokinase receptor (suPAR) is a possible causative factor. It is possible that more than one factor exists. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H166292499#H166292499\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Soluble urokinase receptor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1107667094\">",
"    <span class=\"h2\">",
"     Recurrent primary non-idopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent primary non-idiopathic FSGS in the native kidney is generally due to genetic mutations, infection, toxins or possibly obesity. Secondary FSGS related to hyperfiltration injury (due to loss of functioning kidney parenchyma) may also recur, if underlying cause is not adequately treated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in the genes encoding the podocyte proteins alpha-actinin-4 (ACTN4), podocin (NPHS2), TRPC6, and CD2AP have been identified as causes of hereditary forms of the disease in the native kidney. Recurrence in patients with podocin has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. One report described recurrence in a patient with a TRPC6 mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1107666570\">",
"     'Risk factors for recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Variants of the MYH9 and APOL1 genes that are prevalent among African Americans are highly associated with an increased risk of developing FSGS in the native kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. MYH9 and APOL1 risk alleles have not been associated with increased risk of recurrence in the allograft. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of primary non-idiopathic FSGS including infection, toxins, or obesity may recur in the allograft, but are uncommon, at least in patients for whom the cause of FSGS in the native kidney is known. In general, the conditions that caused FSGS in the native kidney are treated prior to transplantation or are contraindications to transplantation. As an example, patients who have FSGS as a result of infection generally have the infection treated prior to transplantation since active infection is a contraindication to transplantation. However, treated HIV infection, which is one of the more common causes of viral-induced FSGS, is no longer a contraindication to transplantation in many centers, and recurrent HIV-associated nephropathy has been reported (personal communication). Extreme obesity usually excludes candidates from transplantation. In general toxins that were known to cause FSGS in the native kidney (including bisphosphonates, anabolic steroids and interferon) would be avoided among transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195632520\">",
"    <span class=\"h2\">",
"     De novo primary idiopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients develop primary FSGS in the transplanted kidney even though they did not have FSGS in their native kidneys. The pathogenesis of de novo primary FSGS in the transplanted kidney is likely the same as that in the native kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The pathogenesis of primary FSGS in the native kidney is extensively reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angiotensin II type 1 (AT1) receptor antibodies were found to correlate with de novo collapsing FSGS in a patient with a third kidney transplant; his original kidney disease was secondary to lupus nephritis. The collapsing FSGS resolved with plasmapheresis and ARB therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195632586\">",
"    <span class=\"h2\">",
"     De novo primary non-idiopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may develop secondary FSGS in the transplanted kidney even though they did not have FSGS in their native kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/48-50,52,53\">",
"     48-50,52,53",
"    </a>",
"    ]. In general, any of the causes of FSGS in the native kidney may also occur in the allograft; these include infections, toxins, or obesity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link&amp;anchor=H2#H2\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Pathogenesis and etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain virus, such as HIV, may cause FSGS in either the native kidney or the allograft. Other viruses are more likely to cause clinically significant disease in allograft recipients because of immunosuppression, and have been associated with FSGS among such patients. These viruses include parvovirus B19, CMV, EBV, and BK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain medications have been associated with FSGS. Of particular importance among transplant recipients, MTOR inhibitors are associated with the development of FSGS that may improve with the discontinuation of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MTOR inhibitors are generally avoided among patients who have FSGS as the cause of ESRD because of the associated increased risk of proteinuria, although there are no data that suggest that MTOR inhibitors are associated with an increased risk of recurrent FSGS.",
"   </p>",
"   <p>",
"    Other medications that have been associated with FSGS include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and other bisphosphonates, anabolic steroids and interferon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link&amp;anchor=H5#H5\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Bisphosphonates and other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary FSGS may result from an adaptive response to glomerular hypertrophy and hyperfiltration, from scarring due to previous injury. In this context, hyperfiltration refers to an adaptive but abnormal increase in single-nephron glomerular filtration that increases the total glomerular filtration rate above the level expected from the reduced number of glomeruli.",
"   </p>",
"   <p>",
"    The glomerulosclerosis in this setting may result from chronic rejection, calcineurin inhibitor nephrotoxicity, hemodynamic factors associated with the glomerular hypertrophy induced by having only one functioning kidney, or reflect age related changes or recurrent disease other than FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/2,49,50,57-59\">",
"     2,49,50,57-59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link&amp;anchor=H15#H15\">",
"     \"Chronic renal allograft nephropathy\", section on 'Glomerular hyperfiltration and hypertrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have recurrent primary FSGS present with proteinuria, which is frequently in the nephrotic range and is often of rapid onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/1\">",
"     1",
"    </a>",
"    ]. Increased protein excretion may be noted in the early post-transplant period; in children, the median time to recurrent proteinuria is approximately 10 to 14 days after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/5,30\">",
"     5,30",
"    </a>",
"    ]. Patients usually have symptoms and signs of nephrotic syndrome including edema, hypoalbuminemia and hyperlipidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/1,5,30\">",
"     1,5,30",
"    </a>",
"    ]. Some patients develop anasarca (ie, generalized and massive edema) with marked peripheral edema, abdominal distension resulting from ascites, marked scrotal or vulvar edema, and severe periorbital edema resulting in swollen shut eyelids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients usually do not have gross hematuria although microscopic hematuria may be present.",
"   </p>",
"   <p>",
"    For reasons that are not well understood, patients who develop recurrent disease may be more likely to have had acute kidney injury in the first week after transplantation and more likely to develop acute rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/3,14,60\">",
"     3,14,60",
"    </a>",
"    ]. Furthermore, graft loss in these patients is most often due to acute rejection rather than progressive glomerulosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, patients who develop de novo FSGS generally present much later; among such patients the onset of proteinuria generally occurs three months or more after transplantation. However, rapidly progressive graft failure can occur among patients with de novo FSGS of collapsing subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/49,50,61\">",
"     49,50,61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1107666570\">",
"     'Risk factors for recurrence'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Histologic variants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;To help detect early recurrence post-transplantation, at risk patients are screened for proteinuria with a random or spot urine protein-to-creatinine ratio, on the first postoperative day, the day of scheduled hospital discharge, weekly for four weeks, and then monthly for one year after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/62\">",
"     62",
"    </a>",
"    ]. If the ratio is greater than 0.5, we usually obtain a 24-hour protein collection to confirm the result obtained with the random urine protein-to-creatinine ratio, although some clinicians do not do this. The rationale underlying aggressive screening is that recurrent primary FSGS may result in the rapid development of nephrotic syndrome with numerous sequelae, including massive volume overload, acute kidney injury and hyperlipidemia. In addition, recurrent primary FSGS commonly leads to loss of the allograft. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prognosis'",
"    </a>",
"    below.) Although the efficacy of immunomodulatory therapies for recurrent FSGS is unproven, early institution of therapy is believed to be more likely to be effective than delayed treatment. (See",
"    <a class=\"local\" href=\"#H698428\">",
"     'Recurrent primary idiopathic FSGS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Protein excretion from native kidneys decreases significantly within one month of transplant; thus proteinuria that is detected more than one month after transplantation is probably from the allograft and should trigger further investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. A renal biopsy should be performed if post-transplantation proteinuria exceeds 1 gram per day and should include electron microscopy to detect early features of FSGS.",
"   </p>",
"   <p>",
"    To ensure the ability to detect recurrent proteinuria following transplantation, some have advocated that patients with significant proteinuria of the native kidney (greater than three",
"    <span class=\"nowrap\">",
"     grams/day)",
"    </span>",
"    should undergo pretransplantation medical nephrectomy (with an ACE inhibitor, angiotensin II receptor blocker, or NSAID), renal ablation, or surgical nephrectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/62\">",
"     62",
"    </a>",
"    ]. However, we believe that nephrectomy is probably only warranted for massive proteinuria, especially associated with malnutrition in children with such disorders as congenital nephrotic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H385206678\">",
"    <span class=\"h2\">",
"     Urinary apolipoprotein A-1 (ApoA-1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased urinary concentration of apoproteinA-1 (ApoA-1), a component of high density lipoprotein (HDL) has been associated with recurrent idiopathic FSGS among transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/33\">",
"     33",
"    </a>",
"    ]. Increased urinary ApoA-1 was initially detected by proteomic analysis in 8 transplant recipients with recurrent FSGS but not in 27 transplant recipients who had nonrecurrent FSGS in the native kidney. Patients with familial FSGS were excluded from the analysis. In an independent validation study, ApoA-1 was detected in 5 of 6 transplant recipients with recurrent FSGS but in only 1 of 34 transplant recipients with nonrecurrent FSGS in the native kidney. Increased ApoA-1 was also not detected in any of 14 transplant recipients with familial FSGS or in any of 30 patients with proteinuria unrelated to FSGS (including 17 transplant recipients and 13 nontransplant recipients). ApoA-1 may provide a useful biomarker for recurrent FSGS although further investigation is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No interventions have been conclusively shown to prevent recurrent primary FSGS in the transplanted kidney. Potential interventions that have been studied include various immunosuppressive medications used for induction,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and prophylactic plasmapheresis.",
"   </p>",
"   <p>",
"    As discussed above, one retrospective study has suggested that the rate of recurrent glomerulonephritis, including FSGS, may be lower in patients who received thymoglobulin (polyclonal rabbit-antithymocyte globulin) compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    and interleukin 2 receptor antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/32\">",
"     32",
"    </a>",
"    ]. Other studies have shown no effect of different immunosuppressive therapies. (See",
"    <a class=\"local\" href=\"#H1107666570\">",
"     'Risk factors for recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although these are insufficient data upon which to base the choice of induction therapy, we generally administer thymoglobulin to most patients undergoing kidney transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=see_link&amp;anchor=H5#H5\">",
"     \"Induction immunosuppressive therapy in renal transplantation in adults\", section on 'Polyclonal antibodies'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1107666570\">",
"     'Risk factors for recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two small studies have suggested that prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    administration may prevent the recurrence of FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. As an example, in one study in which 27 patients who received rituximab at the time of transplantation were compared with 14 historical controls who did not receive rituximab, rituximab treatment was associated with a lower incidence of posttransplant proteinuria and stabilization of glomerular filtration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/66\">",
"     66",
"    </a>",
"    ]. In another study, rituximab may have prevented the recurrence of FSGS in patients who had already lost a previous allograft to recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Second transplants'",
"    </a>",
"    below.) However, we suggest not using rituximab to prevent recurrence until more conclusive data are available.",
"   </p>",
"   <p>",
"    Prophylactic plasmapheresis does not appear to decrease the rate of recurrence after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H954569040\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent focal segmental glomerulosclerosis (FSGS) is suspected when abnormal proteinuria is detected by routine screening or when the patient develops signs and symptoms of nephrotic syndrome and is shown to have significant proteinuria. A definitive diagnosis of FSGS in the renal allograft is made based upon renal biopsy findings in the setting of significant proteinuria (greater than 1",
"    <span class=\"nowrap\">",
"     gram/day).",
"    </span>",
"    Allograft histology demonstrates characteristic features of FSGS that are identical to FSGS in the native kidney. Some have suggested that the earliest finding in recurrent FSGS is foot process effacement observed by electron microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/62\">",
"     62",
"    </a>",
"    ]; however, a definitive diagnosis cannot be made unless characteristic features of FSGS are visible by light microscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Histologic variants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are diagnosed with FSGS by biopsy require evaluation for underlying causes and associated conditions, since the histologic features do not reliably distinguish between idiopathic and non-idiopathic forms of FSGS nor between primary and secondary FSGS, and since there is significant overlap in the clinical features. (See",
"    <a class=\"local\" href=\"#H1718545898\">",
"     'Evaluation after diagnosis of FSGS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1045083317\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of FSGS prior to biopsy includes all causes of proteinuria, all which present in the native kidney but may also occur in the allograft, regardless of the cause of failure of the native kidney. This differential is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=see_link&amp;anchor=H7#H7\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Causes of glomerular disease according to presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1718545898\">",
"    <span class=\"h1\">",
"     EVALUATION AFTER DIAGNOSIS OF FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of FSGS is confirmed by analysis of histology obtained by allograft biopsy, viral etiologies and toxins should be excluded, if possible. Medications should be reviewed and potentially causative medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or, among patients with collapsing FSGS, bisphosphonates, should be discontinued.",
"   </p>",
"   <p>",
"    Evidence for infection should be sought, preferably via PCR or direct immunostaining. We test for parvovirus B19, CMV, EBV, BK, HCV and, if risk factors are present, HIV, by polymerase chain reaction (PCR). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Etiology and pathogenesis'",
"    </a>",
"    above.) Patients who have PCR-evidence of infection should be treated for the viral infection if possible, to see if proteinuria responds. The treatment of specific viral infection among renal transplant recipients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally evaluate all patients with recurrent FSGS for hypogammaglobulinemia, which is associated with viral infections that may cause FSGS and has been observed in recipients of solid organ transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Some clinicians however, only evaluate for hypogammaglobulinemia among patients who are undergoing plasmapheresis, which is used for the treatment of primary idiopathic FSGS, in order to ascertain that patients are receiving adequate repletion of antibodies that are removed during plasmapheresis sessions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698428\">",
"    <span class=\"h2\">",
"     Recurrent primary idiopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section addresses the treatment of recurrent primary idiopathic FSGS rather than recurrent primary non-idiopathic FSGS. However, as described above, the identification of recurrent primary idiopathic FSGS is not straightforward since FSGS related to toxins, viral infection, hypogammaglobulinemia or hyperfiltration injury may present with identical clinical and histologic features. Thus viral infection and hypogammaglobulinemia should be treated prior to instituting treatment that is specifically directed to recurrent primary idiopathic FSGS. The treatment of specific viral infection among renal transplant recipients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even among patients who have no evidence of viral infection or hypogammaglobulinemia and who are not on a medication known to cause FSGS, primary non-idiopathic FSGS or secondary FSGS may be difficult to exclude. Our approach to treatment is determined by the timing of onset of recurrence and in part by the severity of proteinuria. We generally treat patients who present within one year of transplantation and who have protein excretion &gt;1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with plasmapheresis. Our rationale is that, compared with those who present later, such patients are more likely to have primary idiopathic FSGS rather than primary non-idiopathic or secondary FSGS, and are thus more likely to respond to plasmapheresis. Reports have suggested that plasmapheresis may induce remission of proteinuria among selected patients with primary idiopathic FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/4,34,36,37,70-73\">",
"     4,34,36,37,70-73",
"    </a>",
"    ]. However, given the absence of conclusive data demonstrating a benefit and given the cost and potential side effects of plasmapheresis, some nephrologists do not routinely administer this therapy to patients with recurrent disease unless the patient is severely nephrotic (ie, markedly low albumin and edema). Among patients who are selected for treatment with plasmapheresis, a typical regimen is 1.5 plasma volume exchanges for three consecutive days and then every other day for a total of two weeks. A small dose of IVIG (ie, 150",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is administered after plasmapheresis sessions to replace depleted antibodies.",
"   </p>",
"   <p>",
"    It is hypothesized that recurrent primary idiopathic FSGS that occurs within a short time after transplantation is caused by a circulating permeability factor. The strongest candidate for the circulating factor, suPAR, was shown to be removed effectively with plasmapheresis with a resulting clinical response in one defining study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/74\">",
"     74",
"    </a>",
"    ]. In this study, two patients who had a reduction in suPAR to near physiologic levels achieved remission of recurrent FSGS while two patients whose suPAR levels remained elevated did not experience remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasmapheresis and protein adsorption have been shown to reduce protein excretion and induce complete remission in at least some cases of recurrent FSGS in multiple other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/12,34,36,37,71\">",
"     12,34,36,37,71",
"    </a>",
"    ]. Initial studies noted only a transient benefit, as the proteinuria returned to pretreatment levels within several weeks in almost all patients (",
"    <a class=\"graphic graphic_figure graphicRef51857 \" href=\"mobipreview.htm?39/6/40045\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/36\">",
"     36",
"    </a>",
"    ]. However, better results were obtained in a subsequent report in which patients with recurrent FSGS were treated with plasma exchange for three consecutive days followed by every other day for a total of nine treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/37\">",
"     37",
"    </a>",
"    ]. Each treatment consisted of the removal of 1.5 plasma volumes with 5 percent albumin used as the replacement fluid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Six of nine patients treated within one week of the onset of proteinuria had a mean reduction in protein excretion from 11.5 to 0.8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and remissions were maintained for up to 27 months. Two patients relapsed and then responded to a repeat course of plasmapheresis. Two of the three nonresponders (as opposed to one of six responders) already had glomerular hyalinosis on renal biopsy, suggesting irreversible injury had occurred prior to the initiation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/75\">",
"     75",
"    </a>",
"    ]. Although definitive data are not available, we try to initiate plasmapheresis early after the onset of recurrent disease before hyalinosis or more severe histologic changes have occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/62,76\">",
"     62,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prolonged beneficial results have also been reported in children treated with plasmapheresis and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 11 children with recurrent FSGS post-transplant, nine were administered plasmapheresis, which was performed 6 to 10 times over 15 to 24 days (with the removal of 1 to 1.5 plasma volumes per treatment based upon patient weight), plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      transiently discontinued) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/35\">",
"       35",
"      </a>",
"      ]. Seven had a persistent remission over a follow-up period of 32 months.",
"     </li>",
"     <li>",
"      In a second report of six children with recurrent FSGS, plasmapheresis (performed 10 times over two weeks followed by one session per week for two months), combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      discontinued for three months) resulted in complete and partial remissions in three and three children, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A definitive conclusion concerning the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in this setting requires further study.",
"   </p>",
"   <p>",
"    Limited evidence suggests that the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , high-dose glucocorticoids, plus plasmapheresis provides sustained remission in patients with recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In a nonrandomized study, 10 adults with recurrent FSGS were treated with intravenous cyclosporine for 14 days followed by oral cyclosporine, high dose glucocorticoids, and prolonged intense plasmapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/78\">",
"     78",
"    </a>",
"    ]. Compared with a historic control group of 19 patients, this regimen significantly improved the rate of complete and sustained remission (90 versus 27 percent). A well-designed clinical trial is required to determine whether this regimen has a role in this setting.",
"   </p>",
"   <p>",
"    We treat all patients who present within one year from transplantation with ACE inhibitors or angiotensin receptor blockers (ARBs) unless contraindications exist. Such treatment has been shown to prevent the progression of most proteinuric renal disease in the non-transplant population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    .)In addition, dyslipidemia should be controlled with statins.",
"   </p>",
"   <p>",
"    We consider patients who present later than one year after transplantation as more likely to have primary non-idiopathic FSGS or secondary FSGS. Such patients are less likely to respond to plasmapheresis compared with patients who present early after transplantation. The treatment of such patients is discussed below. (See",
"    <a class=\"local\" href=\"#H146873049\">",
"     'Recurrent and de novo primary non-idiopathic FSGS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146873049\">",
"    <span class=\"h2\">",
"     Recurrent and de novo primary non-idiopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific treatment of primary non-idiopathic FSGS in the allograft depends in part upon the identification of an underlying cause. Thus viral infection and hypogammaglobulinemia should be excluded or treated prior to instituting treatment that is specifically directed to secondary FSGS. The treatment of specific viral infection among renal transplant recipients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of specific viral infection among renal transplant recipients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=see_link\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=see_link\">",
"     \"Hepatitis C virus infection and renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=see_link\">",
"     \"Renal disease associated with hepatitis C virus after renal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medications should be reviewed and all agents that are known to be associated with FSGS should be discontinued.",
"   </p>",
"   <p>",
"    Among patients who have no evidence of viral infection or hypogammaglobulinemia and who are not on a medication known to cause FSGS, primary nonidiopathic FSGS may be difficult to exclude. Our approach to treatment of such patients is determined by the timing of onset of recurrence and in part by the severity of proteinuria. As described above, patients who present within one year from transplantation are more likely to have primary idiopathic than primary non-idiopathic or secondary FSGS. The treatment of such patients is discussed above. (See",
"    <a class=\"local\" href=\"#H519568810\">",
"     'Recurrent primary idiopathic FSGS'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients who present beyond one year from transplantation, and who do not have an underlying cause such as viral infection identified, the treatment depends upon the magnitude of proteinuria. We treat with immunosuppressive therapy patients who present with protein excretion greater than 3.5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    We do not treat with immunosuppressive therapy patients who present with protein excretion less than 3.5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    Among patients who are selected for treatment, we administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    100 mg orally daily. Virtually all transplantation patients are already being treated with a metabolite such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil as part of their immunosuppressive regimen. The antimetabolite must be stopped when cyclophosphamide is started. Thus, the cyclophosphamide is a replacement for the antimetabolite. The administration of cyclophosphamide has been tried in selected cases of recurrent FSGS with variable success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/79,80\">",
"     79,80",
"    </a>",
"    ] and in primary FSGS in the native kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. The dose of cyclophosphamide should be adjusted for renal function. (",
"    <a class=\"graphic graphic_table graphicRef60883 \" href=\"mobipreview.htm?6/31/6652\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If there is no response to this agent after 6 to 12 weeks, we attempt plasmapheresis as described above, despite the lack of data suggesting a benefit.",
"   </p>",
"   <p>",
"    The rationale for using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    without plasmapheresis is largely derived from studies of patients with primary idiopathic FSGS in the native kidney for whom cyclophosphamide may be a reasonable alternative to calcineurin inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Cytotoxic therapy'",
"    </a>",
"    .). A small case series has reported the successful treatment of recurrent FSGS with cyclophosphamide 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other immunosuppressive agents have been less well studied. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is often beneficial for the primary disease (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\"",
"    </a>",
"    ), it does not appear to prevent recurrence in the transplant when given as part of the initial immunosuppressive regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Whether cyclosporine may be of some benefit in those patients who were not on a calcineurin inhibitor at the time of recurrence is not known.",
"   </p>",
"   <p>",
"    By comparison, limited evidence suggests that recurrent nephrotic syndrome in children, which is most commonly due to FSGS, may be successfully treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled French study, recurrent proteinuria disappeared in 14 of 17 children after the administration of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      for a mean period of 21 days; three of the 14 also received plasmapheresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/87\">",
"       87",
"      </a>",
"      ]. At a mean follow-up of 4.1 years, 11 children remained in remission.",
"     </li>",
"     <li>",
"      In a second series, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      dose was increased gradually in 16 patients with recurrent disease until either remission was induced or toxicity occurred; seven were also treated with plasma exchange [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/88\">",
"       88",
"      </a>",
"      ]. Remission was induced in 13 (81 percent, with four administered plasma exchange), with doses of cyclosporine required ranging from 6 to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Once remission was achieved, cyclosporine was tapered to a standard post",
"      <strong>",
"       -",
"      </strong>",
"      transplant regimen dose. At follow-up of 10 months to 12 years, 11 of 13 had a functioning allograft.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism by which calcineurin inhibitors decrease proteinuria may be via a direct effect on the cytoskeleton rather than an immunosuppressive effect. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=see_link&amp;anchor=H6#H6\">",
"     \"Biology of glomerular podocytes\", section on 'Foot process effacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged, daily, high dose glucocorticoids are routinely used for the treatment of FSGS in non-transplant patients. Although there are only limited reports of this treatment modality for recurrent FSGS, there may be a role for steroids in this setting. In one report, two children developed recurrent FSGS after glucocorticoids were changed from daily to alternate day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/89\">",
"     89",
"    </a>",
"    ]. Both patients initially responded to prolonged, daily, high dose corticosteroids, but subsequently relapsed with lower dose daily steroids.",
"   </p>",
"   <p>",
"    Other agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and galactose, have been tried with variable success [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/12,90-94\">",
"     12,90-94",
"    </a>",
"    ]. A few small studies have suggested that prophylactic rituximab may prevent recurrent disease. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two case reports have described improved proteinuria and stabilization of estimated GFR with galactose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We treat all patients who present beyond one year from transplantation with ACE inhibitors or angiotensin receptor blockers (ARBs) unless contraindications exist. Such treatment has been shown to prevent the progression of most proteinuric renal disease in the non-transplant population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H11#H11\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Effect of renin-angiotensin system inhibitors on progression of CKD'",
"    </a>",
"    .)In addition, dyslipidemia should be controlled with statins.",
"   </p>",
"   <p>",
"    Patients with recurrent FSGS in the setting of homozygous or compound heterozygous podocin mutations should still be offered aggressive therapy, since most will respond.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146874968\">",
"    <span class=\"h2\">",
"     De novo primary idiopathic FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients who do not have a known cause for FSGS and are not known to have had FSGS in the native kidney is the same as that for recurrent FSGS and depends upon the timing of onset of proteinuria and the degree of proteinuria. (See",
"    <a class=\"local\" href=\"#H698428\">",
"     'Recurrent primary idiopathic FSGS'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H146873049\">",
"     'Recurrent and de novo primary non-idiopathic FSGS'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent focal segmental glomerulosclerosis (FSGS) may result in allograft loss in a significant number of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, among 25 patients with recurrent FSGS, graft failure occurred in 14 (56 percent) at an average of 24 months after diagnosis of recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series, among 57 transplant recipients with FSGS (of which 30 were documented by biopsy to be recurrent FSGS), graft failure occurred in 37 (63 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis of de novo primary idiopathic FSGS is poor; untreated primary FSGS often follows a progressive course to end-stage renal disease (ESRD). The rate of spontaneous complete remission among patients with nephrotic syndrome is unknown, but is probably less than 10 percent. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of primary focal segmental glomerulosclerosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of recurrent or de novo primary non-idiopathic and secondary FSGS depends upon the underlying cause. In the native kidney, viral-induced FSGS tends to progress to ESRD whereas FSGS related to hyperfiltration and obesity usually follows a more indolent course. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link&amp;anchor=H17#H17\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\", section on 'Prognosis'",
"    </a>",
"    .) Virtually no studies have examined prognosis of specific types of FSGS in the allograft but one would expect that FSGS would carry a worse prognosis in a transplanted kidney compared with a native kidney given the lower number of functioning nephrons available to sustain GFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CHOICE OF LIVING OR DECEASED TRANSPLANT DONOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with FSGS, we suggest the use of a living donor if available.",
"   </p>",
"   <p>",
"    Among patients with FSGS, living-related donor kidneys are associated with equal or better outcomes compared with deceased donor kidneys:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from the Recurrent Allograft Disease Registry (RADR) found a similar rate of recurrence among adult recipients of living or deceased donor kidneys [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/19\">",
"       19",
"      </a>",
"      ]. Based upon a Cox proportional hazards model, a deceased donor kidney was more likely than a living-related kidney to be lost in patients with recurrent disease.",
"     </li>",
"     <li>",
"      Analysis of data from the USRDS study of adult recipients demonstrated a similar risk for graft loss from recurrent FSGS between living and deceased donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/8\">",
"       8",
"      </a>",
"      ]. This analysis identified a graft survival advantage for living donor kidneys over deceased donor kidneys [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report based on the North American Pediatric Renal Transplant Cooperative Study database (NAPRTCS) compared transplant outcomes of 752 pediatric patients with FSGS with 5732 control patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/14\">",
"       14",
"      </a>",
"      ]. Graft survival at five years was not statistically different between living donors and deceased donors (69 versus 60 percent), suggesting that among FSGS patients, the survival advantage that is usually observed with a living donor kidney was lost [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/14\">",
"       14",
"      </a>",
"      ]. Similar results were seen in the subgroup of adolescents up to age 17, with graft losses of 56 versus 51 percent with living and deceased donors, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/60\">",
"       60",
"      </a>",
"      ]. In both analyses, graft loss was similar in living and deceased donated kidneys. Notably, graft survival was markedly worse in pediatric patients with FSGS compared with those with other kidney diseases, a difference that was not accounted for by recurrence alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, by contrast to the studies cited above, according to an analysis of the USRDS, recipients with FSGS and a zero mismatched living donor kidney had an excellent death censored graft survival of 95 percent at five years, which was significantly better than deceased donor allografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the use of a living related donor kidney is more likely to allow preemptive transplantation (ie, prior to the initiation of dialysis) which has been associated with improved patient outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=see_link&amp;anchor=H2#H2\">",
"     \"Dialysis issues prior to and after renal transplantation\", section on 'Preemptive transplantation and outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the clinician should be cautious with a donor with a heterozygous podocin (NPHS2) mutation, since as the clinical significance of such a lesion is currently unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/62,98\">",
"     62,98",
"    </a>",
"    ]. Commercial tests are available to detect NPHS2 mutations (but not mutations in the alpha-actinin-4, TRPC6, or CD2AP genes).",
"   </p>",
"   <p>",
"    We test potential living donors who are siblings to determine whether they carry the suspect podocin (NPHS2) gene. We do not use heterozygote donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SECOND TRANSPLANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop recurrent disease in the first transplant are at very high risk (up to 75 percent) for recurrence in subsequent allografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Graft loss due to recurrent disease is seen in 10 to 80 percent of these patients, with the prognosis being worse in patients with persistent nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians have suggested that, if a first graft is lost to recurrent disease, a second transplant should be delayed for one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/99\">",
"     99",
"    </a>",
"    ]. This delay, which may be most appropriate if recurrence is rapid, may result in the disappearance of the circulating nephrotoxic factors that are responsible for the glomerular injury. However, the efficacy of this approach is not proven.",
"   </p>",
"   <p>",
"    A case report and a small uncontrolled study suggested that preemptive plasmapheresis lowers the risk of recurrent FSGS among patients at high risk for recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/90,100\">",
"     90,100",
"    </a>",
"    ]. A well-designed larger trial is required to determine whether plasmapheresis has any role in this setting.",
"   </p>",
"   <p>",
"    A small case series suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    may prevent FSGS recurrence in a second transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/59/33722/abstract/65\">",
"     65",
"    </a>",
"    ]. Four patients who underwent a second transplant because the first one failed due recurrence of FSGS received rituximab (four patients received a single dose [375",
"    <span class=\"nowrap\">",
"     mg/m2]",
"    </span>",
"    immediately after transplantation and two patients received an additional dose at day seven). All patients were free of recurrence at follow-ups between 12 to 54 months long.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21563250\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary idiopathic focal and segmental glomerulosclerosis (FSGS) commonly recurs in the transplanted kidney. The reported recurrence rate averages about 30 percent, although this rate includes cases of FSGS due to infection, medications or hyperfiltration injury, which is much less likely than primary idiopathic FSGS to recur; as a result the real recurrence rate of primary idiopathic FSGS is probably much higher. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1045081412\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major risk factors for recurrence include childhood onset of initial disease, rapid progression of initial disease, and a history of recurrence in a prior allograft. In the United States, white recipients of African American kidneys may be at particularly high risk of recurrence. The histologic subtype of FSGS does not appear to predict the risk of recurrence. A family history of FSGS generally predicts a low risk of recurrence. (See",
"      <a class=\"local\" href=\"#H1107666570\">",
"       'Risk factors for recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have recurrent primary FSGS typically present with the rapid onset of proteinuria, which is frequently in the nephrotic range. To detect early recurrence, at risk patients are screened for proteinuria with a random or spot urine protein-to-creatinine ratio, on the first postoperative day, the day of scheduled hospital discharge, weekly for four weeks, and then monthly for one year after transplantation. If the ratio is greater than 0.5, a 24-hour protein collection should be obtained for confirmation. A renal biopsy should be performed if post-transplantation proteinuria exceeds 1 gram per day. The diagnosis of FSGS is made by renal biopsy findings in the setting of significant proteinuria (greater than 1",
"      <span class=\"nowrap\">",
"       gram/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H954569040\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No immunosuppressive therapies have been conclusively shown to prevent FSGS in the transplanted kidney. Two small studies have suggested that prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      administration may prevent the recurrence of FSGS. Among transplant recipients who have a history of FSGS as a cause of ESRD, we suggest not using rituximab or prophylactic plasmapheresis to prevent recurrence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment of patients with recurrent FSGS is not known. Our approach includes nonimmunosuppressive treatment for all patients and immunosuppressive treatment for selected patients depending upon the timing of recurrence, severity of proteinuria and presence of",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      of nephrotic syndrome. (See",
"      <a class=\"local\" href=\"#H698428\">",
"       'Recurrent primary idiopathic FSGS'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For all patients with recurrent FSGS, we recommend treatment with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Such treatment has been shown to prevent the progression of most proteinuric renal disease in the non-transplant population.",
"     </li>",
"     <li>",
"      For patients who have polymerase chain reaction (PCR)-evidence of infection with a virus that is associated with FSGS (HIV, parvovirus B19, CMV, EBV, BK, and HCV) we suggest anti-viral treatment if possible, prior to administering plasmapheresis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who do not respond to anti-viral treatment with a reduction in proteinuria, we administer plasmapheresis as described below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have significant proteinuria (ie, &gt;1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      despite ACE inhibitors or ARBS and who have no evidence of viral infection and who present within one year of transplantation we suggest plasmapheresis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      However, given the absence of conclusive data demonstrating a benefit and given the cost and potential side effects of plasmapheresis, some nephrologists do not routinely administer this therapy to patients with recurrent disease unless the patient has nephrotic range proteinuria (ie, &gt;3.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      and significant signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of nephrotic syndrome despite ACE inhibitors or ARBS. For patients who are selected for treatment with plasmapheresis, a typical regimen is 1.5 plasma volume exchanges for three consecutive days and then every other day for a total of two weeks. A small dose of IVIG (ie, 150",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      is administered after plasmapheresis sessions to replace depleted antibodies.",
"     </li>",
"     <li>",
"      For patients who present beyond one year from transplantation and who have nephrotic range proteinuria (ie, &gt;3.5",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      and significant signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of nephrotic syndrome despite ACE inhibitors or ARBS, and who have no evidence of viral infection or hypogammaglobulinemia, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      rather than plasmapheresis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We administer 100 mg orally daily. Since virtually all renal transplantation patients are already being treated with a metabolite such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil as part of their immunosuppressive regimen, the antimetabolite must be stopped when cyclophosphamide is started. The dose of cyclophosphamide should be adjusted for renal function. For patients who do not respond to cyclophosphamide with a reduction in protein excretion after 6 to 12 weeks, we suggest plasmapheresis as described above (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who present beyond one year from transplantation and who have proteinuria &lt;3.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      we suggest continuing their standard immunosuppressive regimen to prevent rejection but not using specific immunosuppressive therapies to treat FSGS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/1\">",
"      Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006; 6:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/2\">",
"      Cheigh JS, Mouradian J, Susin M, et al. Kidney transplant nephrotic syndrome: relationship between allograft histopathology and natural course. Kidney Int 1980; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/3\">",
"      Kim EM, Striegel J, Kim Y, et al. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 1994; 45:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/4\">",
"      Pinto J, Lacerda G, Cameron JS, et al. Recurrence of focal segmental glomerulosclerosis in renal allografts. Transplantation 1981; 32:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/5\">",
"      Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992; 2:S258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/6\">",
"      Striegel JE, Sibley RK, Fryd DS, Mauer SM. Recurrence of focal segmental sclerosis in children following renal transplantation. Kidney Int Suppl 1986; 19:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/7\">",
"      Lewis EJ. Recurrent focal sclerosis after renal transplantation. Kidney Int 1982; 22:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/8\">",
"      Abbott KC, Sawyers ES, Oliver JD 3rd, et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001; 37:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/9\">",
"      Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 2001; 12:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/10\">",
"      Ghiggeri GM, Carraro M, Vincenti F. Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant 2004; 19:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/11\">",
"      Briggs JD, Jones E. Recurrence of glomerulonephritis following renal transplantation. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. Nephrol Dial Transplant 1999; 14:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/12\">",
"      Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/13\">",
"      Briganti EM, Russ GR, McNeil JJ, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 2002; 347:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/14\">",
"      Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/15\">",
"      D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/16\">",
"      IJpelaar DH, Farris AB, Goemaere N, et al. Fidelity and evolution of recurrent FSGS in renal allografts. J Am Soc Nephrol 2008; 19:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/17\">",
"      Canaud G, Dion D, Zuber J, et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2010; 25:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/18\">",
"      Fogo AB. The spectrum of FSGS: does pathology matter? Nephrol Dial Transplant 2010; 25:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/19\">",
"      Hariharan S, Adams MB, Brennan DC, et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 1999; 68:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/20\">",
"      Dantal J, Baatard R, Hourmant M, et al. Recurrent nephrotic syndrome following renal transplantation in patients with focal glomerulosclerosis. A one-center study of plasma exchange effects. Transplantation 1991; 52:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/21\">",
"      Shimizu A, Higo S, Fujita E, et al. Focal segmental glomerulosclerosis after renal transplantation. Clin Transplant 2011; 25 Suppl 23:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/22\">",
"      Conlon PJ, Lynn K, Winn MP, et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. Kidney Int 1999; 56:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/23\">",
"      Felldin M, Nord&eacute;n G, Svalander C, Nyberg G. Focal segmental glomerulosclerosis in a kidney transplant population: hereditary and sporadic forms. Transpl Int 1998; 11:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/24\">",
"      Carraro M, Caridi G, Bruschi M, et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/25\">",
"      Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/26\">",
"      Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/27\">",
"      Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/28\">",
"      Jungraithmayr TC, Hofer K, Cochat P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 2011; 22:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/29\">",
"      Schachter ME, Monahan M, Radhakrishnan J, et al. Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression. Clin Nephrol 2010; 74:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/30\">",
"      Fuentes GM, Meseguer CG, Carrion AP, et al. Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr Nephrol 2010; 25:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/31\">",
"      Pham PT, Pham PC. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol Dial Transplant 2012; 27:2965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/32\">",
"      Pascual J, Mezrich JD, Djamali A, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation 2007; 83:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/33\">",
"      Lopez-Hellin J, Cantarell C, Jimeno L, et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant 2013; 13:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/34\">",
"      Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/35\">",
"      Dall'Amico R, Ghiggeri G, Carraro M, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999; 34:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/36\">",
"      Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/37\">",
"      Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/38\">",
"      Sharma M, Sharma R, McCarthy ET, Savin VJ. \"The FSGS factor:\" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999; 10:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/39\">",
"      Sharma M, Sharma R, Reddy SR, et al. Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 2002; 73:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/40\">",
"      Candiano G, Musante L, Carraro M, et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/41\">",
"      Gallon L, Leventhal J, Skaro A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012; 366:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/42\">",
"      Srivastava T, Garola RE, Kestila M, et al. Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol 2006; 21:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/43\">",
"      Becker-Cohen R, Bruschi M, Rinat C, et al. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 2007; 7:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/44\">",
"      Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/45\">",
"      Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/46\">",
"      Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/47\">",
"      Pollak MR. Kidney disease and African ancestry. Nat Genet 2008; 40:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/48\">",
"      Babayeva S, Miller M, Zilber Y, et al. Plasma from a case of recurrent idiopathic FSGS perturbs non-muscle myosin IIA (MYH9 protein) in human podocytes. Pediatr Nephrol 2011; 26:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/49\">",
"      Meehan SM, Pascual M, Williams WW, et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 1998; 65:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/50\">",
"      Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis 1999; 33:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/51\">",
"      Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 2013; 368:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/52\">",
"      Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy. Semin Nephrol 2003; 23:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/53\">",
"      Barsoum NR, Bunnapradist S, Mougdil A, et al. Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. Am J Transplant 2002; 2:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/54\">",
"      Li RM, Branton MH, Tanawattanacharoen S, et al. Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol 2002; 13:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/55\">",
"      Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/56\">",
"      Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/57\">",
"      El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/58\">",
"      Cheigh JS, Mouradian J, Soliman M, et al. Focal segmental glomerulosclerosis in renal transplants. Am J Kidney Dis 1983; 2:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/59\">",
"      Cosio FG, Frankel WL, Pelletier RP, et al. Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival. Am J Kidney Dis 1999; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/60\">",
"      Baum MA, Ho M, Stablein D, et al. Outcome of renal transplantation in adolescents with focal segmental glomerulosclerosis. Pediatr Transplant 2002; 6:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/61\">",
"      Swaminathan S, Lager DJ, Qian X, et al. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 2006; 21:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/62\">",
"      Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/63\">",
"      D'Cunha PT, Parasuraman R, Venkat KK. Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation. Am J Transplant 2005; 5:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/64\">",
"      Myslak M, Amer H, Morales P, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006; 6:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/65\">",
"      Audard V, Kamar N, Sahali D, et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int 2012; 25:e62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/66\">",
"      Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3:85ra46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/67\">",
"      Gonzalez E, Ettenger R, Rianthavorn P, et al. Preemptive plasmapheresis and recurrence of focal segmental glomerulosclerosis in pediatric renal transplantation. Pediatr Transplant 2011; 15:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/68\">",
"      Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/69\">",
"      Boddana P, Webb LH, Unsworth J, et al. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon? Clin Transplant 2011; 25:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/70\">",
"      Laufer J, Ettenger RB, Ho WG, et al. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988; 46:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/71\">",
"      Artero M, Biava C, Amend W, et al. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 1992; 92:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/72\">",
"      Torres VE, Velosa JA, Holley KE, et al. Meclofenamate treatment of recurrent idiopathic nephrotic syndrome with focal segmental glomerulosclerosis after renal transplantation. Mayo Clin Proc 1984; 59:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/73\">",
"      Matalon A, Markowitz GS, Joseph RE, et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol 2001; 56:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/74\">",
"      Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/75\">",
"      Cheong HI, Han HW, Park HW, et al. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2000; 15:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/76\">",
"      European best practice guidelines for renal transplantation (Part 2). Nephrol Dial Transplant 2002; 17(Suppl 4):4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/77\">",
"      Hariharan S. Recurrent and de novo diseases after renal transplantation. Semin Dial 2000; 13:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/78\">",
"      Canaud G, Zuber J, Sberro R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant 2009; 9:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/79\">",
"      Kershaw DB, Sedman AB, Kelsch RC, Bunchman TE. Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. Clin Transplant 1994; 8:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/80\">",
"      Saleem MA, Ramanan AV, Rees L. Recurrent focal segmental glomerulosclerosis in grafts treated with plasma exchange and increased immunosuppression. Pediatr Nephrol 2000; 14:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/81\">",
"      Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994; 23:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/82\">",
"      Siegel NJ, Gaudio KM, Krassner LS, et al. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981; 19:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/83\">",
"      Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988; 113:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/84\">",
"      Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. Arch Dis Child 1987; 62:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/85\">",
"      Banfi G, Colturi C, Montagnino G, Ponticelli C. The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. Transplantation 1990; 50:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/86\">",
"      Vincenti F, Biava C, Tomlanovitch S, et al. Inability of cyclosporine to completely prevent the recurrence of focal glomerulosclerosis after kidney transplantation. Transplantation 1989; 47:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/87\">",
"      Salomon R, Gagnadoux MF, Niaudet P. Intravenous cyclosporine therapy in recurrent nephrotic syndrome after renal transplantation in children. Transplantation 2003; 75:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/88\">",
"      Raafat RH, Kalia A, Travis LB, Diven SC. High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 2004; 44:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/89\">",
"      Hanevold CD, Greenbaum LA. Nephrotic syndrome after conversion to alternate day steroids in two children with a history of recurrent FSGS. Pediatr Transplant 2003; 7:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/90\">",
"      Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007; 20:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/91\">",
"      Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 2007; 67:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/92\">",
"      Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 2008; 8:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/93\">",
"      Apeland T, Hartmann A. Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation. Nephrol Dial Transplant 2008; 23:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/94\">",
"      Dello Strologo L, Guzzo I, Laurenzi C, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 2009; 88:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/95\">",
"      Jhaveri KD, Naber TH, Wang X, et al. Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation. Transplantation 2011; 91:e35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/96\">",
"      De Smet E, Rioux JP, Ammann H, et al. FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrol Dial Transplant 2009; 24:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/97\">",
"      Cibrik DM, Kaplan B, Campbell DA, et al. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant 2003; 3:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/98\">",
"      Niaudet P. Podocin and nephrotic syndrome: implications for the clinician. J Am Soc Nephrol 2004; 15:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/99\">",
"      Hosenpud J, Piering WF, Garancis JC, Kauffman HM. Successful second kidney transplantation in a patient with focal glomerulosclerosis. A case report. Am J Nephrol 1985; 5:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/59/33722/abstract/100\">",
"      Gohh RY, Yango AF, Morrissey PE, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005; 5:2907.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7342 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33722=[""].join("\n");
var outline_f32_59_33722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21563250\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1110880582\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1045081412\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1107666570\">",
"      Risk factors for recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1173618337\">",
"      - Urinary apolipoprotein A-1 (ApoA-1)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519568810\">",
"      Recurrent primary idiopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1107667094\">",
"      Recurrent primary non-idopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195632520\">",
"      De novo primary idiopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195632586\">",
"      De novo primary non-idiopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H385206678\">",
"      Urinary apolipoprotein A-1 (ApoA-1)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H954569040\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1045083317\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1718545898\">",
"      EVALUATION AFTER DIAGNOSIS OF FSGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H698428\">",
"      Recurrent primary idiopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146873049\">",
"      Recurrent and de novo primary non-idiopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146874968\">",
"      De novo primary idiopathic FSGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CHOICE OF LIVING OR DECEASED TRANSPLANT DONOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SECOND TRANSPLANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21563250\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7342|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/6/40045\" title=\"figure 1\">",
"      Plasmapheresis in recurrent FGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7342|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/31/6652\" title=\"table 1\">",
"      Adjusting cyclophosphamide dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9304?source=related_link\">",
"      Biology of glomerular podocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31289?source=related_link\">",
"      Hepatitis C virus infection and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32649?source=related_link\">",
"      Induction immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3928?source=related_link\">",
"      Renal disease associated with hepatitis C virus after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34714?source=related_link\">",
"      Treatment of primary focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_59_33723="Drugs asso with NMS";
var content_f32_59_33723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that can cause neuroleptic malignant syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Neuroleptic agents",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Aripiprazole",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Chlorpromazine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Clozapine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Fluphenazine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Haloperidol",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Olanzapine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Paliperidone",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Perphenazine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Quetiapine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Risperidone",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Thioridazine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Ziprasidone",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           Antiemetic agents",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Domperidone",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Droperidol",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Metoclopromide",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Prochlorperazine",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Promethazine",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33723=[""].join("\n");
var outline_f32_59_33723=null;
var title_f32_59_33724="Etiology dysuria in children and adolescents";
var content_f32_59_33724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55819&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of dysuria in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infants and children",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adolescents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic illnesses",
"       </td>",
"       <td>",
"        <p>",
"         Stevens-Johnson syndrome",
"        </p>",
"        <p>",
"         Behcet's syndrome",
"        </p>",
"        <p>",
"         Reactive arthritis (formerly Reiter syndrome)",
"        </p>",
"        <p>",
"         Varicella",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Stevens-Johnson syndrome",
"        </p>",
"        <p>",
"         Behcet's syndrome",
"        </p>",
"        <p>",
"         Reactive arthritis (formerly Reiter syndrome)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary infections",
"       </td>",
"       <td>",
"        <p>",
"         Cystitis (viral or bacterial)",
"        </p>",
"        <p>",
"         Pyelonephritis",
"        </p>",
"        <p>",
"         Vaginitis",
"        </p>",
"        <p>",
"         Genital herpes",
"        </p>",
"        <p>",
"         Balanitis/balanoposthitis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Urethritis",
"        </p>",
"        <p>",
"         Cervicitis",
"        </p>",
"        <p>",
"         Vaginitis",
"        </p>",
"        <p>",
"         Pelvic inflammatory disease",
"        </p>",
"        <p>",
"         Genital herpes",
"        </p>",
"        <p>",
"         Cystitis (viral or bacterial)",
"        </p>",
"        <p>",
"         Pyelonephritis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other genital conditions",
"       </td>",
"       <td>",
"        <p>",
"         Nonspecific&nbsp; (chemical ) urethritis",
"        </p>",
"        <p>",
"         Lichen sclerosis",
"        </p>",
"        <p>",
"         Virginal vaginal ulcers",
"        </p>",
"        <p>",
"         Labial adhesions",
"        </p>",
"        <p>",
"         Local trauma (eg, sexual abuse, masturbation)",
"        </p>",
"        <p>",
"         Urethral stricture",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nonspecific&nbsp; (chemical) urethritis",
"        </p>",
"        <p>",
"         Virginal vaginal ulcers",
"        </p>",
"        <p>",
"         Local trauma (eg, sexual activity, masturbation)",
"        </p>",
"        <p>",
"         Urethral stricture",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miscellaneous",
"       </td>",
"       <td>",
"        <p>",
"         Chemical irritation",
"        </p>",
"        <p>",
"         Urinary stones",
"        </p>",
"        <p>",
"         Idiopathic hypercalciuria",
"        </p>",
"        <p>",
"         Idiopathic hyperuricosuria",
"        </p>",
"        <p>",
"         Sexual abuse",
"        </p>",
"        <p>",
"         Dysfunction elimination",
"        </p>",
"        <p>",
"         Psychogenic urethritis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Psychogenic urethritis",
"        </p>",
"        <p>",
"         Urinary&nbsp;stones",
"        </p>",
"        <p>",
"         Idiopathic hypercalciuria",
"        </p>",
"        <p>",
"         Idiopathic hyperuricosuria",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Related entities",
"       </td>",
"       <td>",
"        Pinworms",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <span class=\"red\">",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33724=[""].join("\n");
var outline_f32_59_33724=null;
var title_f32_59_33725="Contents: ID calculators";
var content_f32_59_33725=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       ID calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			ID calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/62/41952\">",
"           Calculator: CURB-65 pneumonia severity score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/42/44705\">",
"           Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/35/4656\">",
"           Calculator: Diagnosis of endocarditis - Duke criteria for definite endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/34/14881\">",
"           Calculator: Multinational Association for Supportive Care in Cancer (MASCC) risk index for patients with neutropenic fever",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/41/2706\">",
"           Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-72331DD9C6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f32_59_33725=[""].join("\n");
var outline_f32_59_33725=null;
var title_f32_59_33726="Devitalization in KCS";
var content_f32_59_33726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe dry eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorescein dye shows devitalized surface epithelial cells because of severe dryness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33726=[""].join("\n");
var outline_f32_59_33726=null;
var title_f32_59_33727="Deforming arthritis in SLE";
var content_f32_59_33727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deforming lupus arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe hand deformities in a 75-year-old woman with lupus for more than 20 years. Such hand abnormalities are very rare.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_59_33727=[""].join("\n");
var outline_f32_59_33727=null;
